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Multi-walled carbon nanotubes (MWCNT) and 60-carbon fullerenes (C60) are important 
engineered nanoparticles (ENP) used across industry.  Exposure to ENP potentially promotes 
cardiovascular detriments.  The hypotheses that exposure to either MWCNT or C60 would 
exacerbate cardiac ischemia/reperfusion (I/R) injury and promote enhanced coronary artery 
contraction in response to endothelin-1 (ET-1) by a cyclooxygenase-mediated mechanism were 
tested.  One day following intratracheal instillation of vehicle, 1, 10 or 100 μg MWCNT in male 
Sprague-Dawley rats, hearts were isolated and mounted on a Langendorff perfusion apparatus.  
Hearts from animals exposed to 100 μg MWCNT exhibited 3x more premature ventricular 
contractions during perfusion at baseline.  Cardiac perfusion was stopped to induce ischemia for 
20 minutes and then restarted to study injuries induced by I/R.  Post-reperfusion myocardial 
infarction expanded 18% in the 100 µg MWCNT group compared to the vehicle group.  We also 
noted that post-ischemia cardiac release of ET-1 was increased 4-fold and coronary reperfusion 
flow was reduced 30% in the 100 µg MWCNT group compared to the vehicle group.  We next 
evaluated isolated coronary artery ET-1-mediated stress (mN/mm
2
) generation by wire 
myography, 24 hours after intratracheal instillation of 100 µg MWCNT or vehicle.  Coronary 
artery stress generation in response to ET-1 was increased 35% in the MWCNT group compared 
to the vehicle group and was dependent on cyclooxygenase/thromboxane signaling.  Similar 
endpoints were examined following C60 exposure.  We measured myocardial infarction 
following I/Rin situ and coronary artery ET-1-mediated stress responses by wire myography, 24 
hours after intratracheal or intravenous administration of vehicle or 28 µg C60.  Myocardial 
infarction expanded between 70% and 110% across all C60 groups.  Coronary artery stress 
generation in response to ET-1 was elevated by 56% in the male intratracheal C60 group 
compared to the vehicle group and was dependent on cyclooxygenase signaling.  ET-1 responses 
in all other C60 groups were not different than vehicle.  These results support the potential for 
pulmonary exposure to carbon-based ENP to exacerbate cardiac I/R injury and promote 
dysfunction in coronary arteries associated with ET-1/cyclooxygenase axis.  Our results indicate 
that therapeutic targeting of ET-1 or cyclooxygenase signaling might prevent cardiovascular 
detriments associated with ENP exposure. 
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CHAPTER 1 
PREAMBLE AND SPECIFIC AIMS 
 
1.1. Preamble 
Inhalation of ultrafine/nanoparticles (NP) associated with air pollution may increase cardiac 
mortality and underlie cardiovascular disease prevalence in the United States (39).  Modern 
technology has increased the use of engineered NP (ENP) in modern goods and likewise human 
occupational exposure to ENP has increased (74).  Pulmonary instillation of ambient ultrafine 
particles (UFP) collected from the lower atmosphere and ENP have both been shown to 
exacerbate cardiac ischemia/reperfusion (I/R) injury (36; 165), but the mechanisms by which the 
injuries increaseare unknown.  Endothelin-1 (ET-1) is important in cardiovascular physiology 
(161), andderangements in ET-1 signaling could contribute to exacerbation of cardiovascular 
injury following NP exposure.  Cyclooxygenases (COX) can also contribute to the regulation of 
vascular tone via the release of prostaglandin derivatives like thromboxane (TXA2) (52), 
especially in cases of inflammation-induced cyclooxygenase-2 (COX-2) expression (138).  
Pulmonary inflammation induced by exposure to NP could activate COX-2, thereby disrupting 
coronary arterial tone and exacerbating cardiac injury. 
 
Multi-walled carbon nanotubes (MWNCT) and 60-carbon fullerenes (C60) are ENP found in a 
growing number of consumer goods (90; 112).  MWCNT and C60 are also gaining promise in 
medical applications as drug delivery devices and contrast imaging agents (133). The 
hydrophobic core of fullerene molecules, like MWCNT and C60, make the ideal carriers for 
hydrophobic pharmacological agents, while functionalization of the normally hydrophobic 
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fullerene surface with hydrophilic moieties can enhance their solubility in physiological systems 
(7).  Manipulation of MWCNT composites and raw C60 during manufacturing processes can 
generate airborne particulate that could potentially be inhaled by workers in the immediate 
environment.  Physiological responses to MWCNT, C60 and other ENP are not well understood 
and should be examined to assess the potential for adverse endpoints. 
 
It is also important to note that both epidemiological and basic science studies indicategender 
disparities to particulate matter exposures with premenopausal females beingmore resistant than 
males to the cardiovascular detriments associated with air pollution constituents (71; 134) and 
less prone to cardiac I/R injury in general (172).  The same gender protection against 
cardiovascular responses to ENP may hold true, but evidence supporting or refuting this claim is 
absent in scientific literature. 
 
Our laboratory has previously reported an exposure mass-dependent expansion of cardiac I/R 
injury, 24 hours following pulmonary instillation of MWCNT in mice (165).  A similar extent of 
I/R myocardial infarct expansion was found in mice following instillation of ultrafine particular 
matter (36).  The purpose of this dissertation project was to explore and identify factors intrinsic 
to the heart that could potentially increase myocardial vulnerability to I/R injury following 
pulmonary exposure to engineered NP.Once identified, these factors could be utilized to assess 
and classify cardiotoxicity of other ENP.  Basal intrinsic heart rhythm, coronary perfusion, 
release of cardiac-active and vascular-active autocrine/paracrine agents, and pharmacological 
stress production generated by isolated coronary artery preparationswere examined following 
pulmonary instillation of MWCNT.  Stress generated by isolated coronary arteries in response to 
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pharmacological agents following exposure to C60 was examined to explore a unified 
mechanism associated with cardiotoxicity resulting from exposure to different types of ENP.  We 
further determined if theresponses were unique to NP exposure at the pulmonary interface and 
whether they were gender-dependent. 
 
1.2. Hypotheses 
We hypothesized that pulmonary instillation of ENP would exacerbate cardiac I/R injury by (i) 
increasing intrinsic cardiac arrhythmia, (ii) increasing the release of ET-1 and thromboxane from 
the heart during cardiac I/R, and (iii) enhancing coronary vascular resistance via ET-
1/thromboxane mediated coronary vasoconstriction.  We further hypothesized that exacerbated 
cardiac I/R injury and enhanced coronary artery stress responses following ENP exposure would 
be exacerbated in males. 
 
1.3 Specific Aims 
The primary aim of this dissertation was to investigate the effects of an acute exposure to ENP 
on subsequent cardiac I/R injury (see Figure 1.1).  The following Specific Aims were developed 
to test the primary and secondary hypotheses. 
Specific Aim 1:  Determine if pulmonary exposure to MWCNTin vivo leads to altered cardiac 
functionbefore and after I/R ex vivo. 
Aim 1.1. - Assess baseline coronary flow, heart rhythm, ET-1 release, and thromboxane release 
in isolated hearts 24 hours following pulmonary instillation of MWCNT or vehicle. 
Aim 1.2. - Determine if the onset of I/R alters coronary flow, heart rhythm, and ET-1 and 
thromboxane release during myocardial reperfusion between the MWCNT and vehicle groups. 
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Specific Aim 2:  Determine if isolated coronary artery contraction is augmented following 
pulmonary exposure to MWCNT or vehicle. 
Aim 2.1 - Assess coronary artery stress generation in response to ET-1 and TXA2 stimulation. 
Aim 2.2 - Determine the role of COX-1 or COX-2 in influencing the stress generation in isolated 
coronary artery preparation. 
Aim 2.3 - Determine if augmented coronary stress generation is endothelial-dependent and/or 
sensitive to receptor antagonism of ET-1 and TXA2 signaling cascades. 
 
Specific Aim 3:  Using an alternative ENP, C60, identify common underlying mechanisms to 
ENP cardiotoxicity. 
Aim 3.1 - Determine effects of pulmonary and intravenous exposure to C60 on cardiac I/R injury. 
Aim 3.2 - Determine effects ofpulmonary andintravenous exposure to C60 on coronary artery 
smooth muscle stress generation in response to ET-1. 
Aim 3.3 - Determine if COX signaling contributes to coronary artery augmented contraction 
following C60 exposure. 
Aim 3.4 - Determine if gender is a discriminator for the extent of NP exposure-mediated cardiac 
I/R injury and/or coronary artery contraction. 
 
1.4. Significance 
Inhalation of NP can injure the cardiovascular system in general.  Epidemiological data suggests 
that short-term exposure (days) to ambient air pollution, including ultrafine particulate, increases 
cardiovascular mortality, cardiovascular hospitalizations, and vascular/endothelial cell 
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dysfunction (16).  Premenopausal females are generally protected against cardiovascular 
dysfunction associated with pulmonary exposure to airborne particulate (71) and diesel 
components (134).  Development of ENP is rapidly advancing in commercial, military, and 
medical industries and as a consequence the potential for human exposures are increasing (133).  
While mechanisms underlying the cardiovascular toxicity of NP inhalation have been proposed 
(39; 144), few mechanisms have been defined.  Given that the number of ENP reaching the 
industrial and medical settings is increasing rapidly, being able to rapidly classify which types of 
ENP are cardiotoxic across genders may be very beneficial.  Therefore, the contents of this 
dissertation should advance the scientific understanding of the physiological mechanisms by 
which negative cardiovascular endpoints result from pulmonary exposure to NP and further 
establish experimental cardiovascular endpoints based on those mechanisms that can be used to 
test the cardiotoxicity of ENP. 
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Figure 1.1 Visual representation of how the aims of this dissertation are related 
 
 
CHAPTER 2 
LITERATURE REVIEW 
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2.1. Cardiovascular disease and the contribution of particulate exposure  
Despite advances in the modern age of medicine and the current volume of knowledge about 
life-style and cardiovascular health, heart disease still accounts for 1 in 3 deaths in the United 
States every year, totaling approximately 788,000 lives lost (62). Of all heart diseases, coronary 
heart disease is the most common and costs the United States $108.9 billion annually for health 
care services, medications and lost productivity (www.cdc.gov/heartdisease).  635,000 
Americans have their first heart attack every year and an additional 280,000 have a second or 
subsequent heart attack (62). 
 
Genetics and sedentary lifestyle are key contributing risk factors for heart disease and 
cardiovascular emergencies, but air pollution and aerosolized particulate matter exposures are 
also key risk factors that are relatively under-recognized (167).  According to the American Lung 
Association’s State of Air Report in 2011, 20% of people in the United States (61 Million 
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Americans) live in areas where spikes in particulate air pollution occur at rates and 
concentrations capable of increasing the probability of heart attack, stroke and cardiovascular-
related premature death.  Several time-course-dependent cardiovascular endpoints have been 
identified from epidemiological, panel and controlled exposure studies.  These include increased 
probability of enhanced arterial vasoconstriction/arterial tone, cardiac arrhythmia, thrombus 
formation and myocardial ischemia, all documented within 24 hours of exposure to air pollution 
(94).  Many of the cardiovascular consequences of air pollution have been linked to the fine 
particulate fraction possessing aerodynamic diameters <2.5 m, but the contributions of the 
ultrafine particulate fraction, those with aerodynamic diameters <0.1 m, have been hard to 
distinguish from gaseous/vapor phase compounds in air pollution mixtures because of variation 
in their relative concentrations and chemical make-up (16; 64).  Gender itself may also have an 
important role in the cardiovascular consequences of air pollution exposure.  Specifically, 
premenopausal females have been shown to be more resistant than males to the cardiovascular 
detriments associated with air pollution constituents (71; 134) and less prone to cardiac I/R 
injury when compared to age-matched males (118; 172).   
 
In general, toxicity to particulate has been expected to increase as particle size decreases on an 
equal mass basis.  This assumption is based on the physical principle that smaller sized particles 
have increased particle numbers and surface areas per mass than larger sized particles of similar 
composition.  The smaller size/mass particles should also have an increased probability of deep 
lung penetration, barrier permeability and interaction with subcellular components within 
physiological systems (74).  Since particle size is expected to dictate lung penetration, a 
consideration of particle aspect ratio is also important because aspect ratio can impact the 
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aerodynamic properties of a particle apart from only the particle’s mass.  For example, a carbon 
nanotube is considered “nano” because of its nanoscale diameter but the micron scale length of a 
carbon nanotube may have an impact on its aerodynamic properties.  In any case, if these 
expectations and assumptions about size/mass-related particle toxicity are true, then it is critical 
to better understand the role that ENP can have in cardiovascular toxicity. 
 
2.2. Mechanisms of cardiovascular toxicity in response to nanoparticles 
Mechanisms of cardiovascular toxicity resulting from inhalation of ambient particulates have 
been proposed (15; 166) and the mechanisms of extrapulmonary toxicity from NP inhalation 
have recently been reviewed (144).  These proposed mechanisms of NP-induced cardiovascular 
toxicity include: (i) direct NP interaction with cells of the cardiovascular system after NP 
translocate from the lung; (ii) pulmonary tissue injury that generates an inflammatory/oxidative 
response that propagates throughout the systemic circulation, and (iii) interaction of NP with 
sensory nerve endings in the lung and subsequent dysregulation of autonomic cardiovascular 
reflexes (see Figure 2.1). 
 
Various inhalation, instillation, and aspiration models of NP exposure in rodents have been 
shown to cause pulmonary inflammation, apoptosis, oxidative stress, fibrosis, damage to the 
pulmonary epithelial barrier, and eventually reductions in lung function (10; 32; 72; 100; 104; 
171; 173; 174; 179).  Following pulmonary exposure to NP, a fraction has been documented to 
translocate systemically (125; 157).  After inhalation CeO2 has been found in the testis, liver, 
spleen, kidney, brain, and epididymis as early as 6 hrs after a single exposure in rats (60).  
Intravenously administered iron oxide NP have been found within hepatic endothelial cells and 
Kupffer cells, but perhaps more importantly withincells within the renal proximal tubule (76).  
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This is important because even if NP thatreach the systemic circulation are filtered through the 
glomerulus, they may be reabsorbed in the renal proximal tubule rather than being cleared by the 
kidney.  Extrapulmonary translocation has been shown to be related to NP size, charge, and 
surface modifications (61; 143) and could occur as a result of increases in pulmonary epithelial 
permeability, allowing NP to pass directly into alveolar capillaries or the lymphatic system (33).  
There has been a large concern for how NP surface chemistry can impact cellular interaction, but 
upon reaching a biological environment soluble proteins (or other biomolecules) may form a 
fluxing molecular corona around NP, ultimately altering biological/NP interactions (51).  The 
flux of biomolecules that comprise the NP corona can be driven by electrochemical interactions, 
like van der Waals and electrostatic charges, causing evolution of the corona constituents as the 
NP moves through the circulation or different cellular environments (113).  The translocation of 
NP may allow for direct interactions with circulating platelets, vascular endothelial cells, 
vascular smooth muscle cells and/or cardiac myocytes.  These interactions may possibly initiate 
cardiovascular oxidative stress, inflammation, fibrosis, and prothrombosis, ultimately impairing 
cardiovascular function. 
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Figure 2.1 Potential mechanisms of nanoparticle-induced cardiovascular toxicity (105) 
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The release of various soluble factors into the circulation after NP exposure may also mediate 
cardiovascular toxicity.  Intratracheal instillation of carbon black NP demonstrated increases in 
pulmonary and hepatic transcription of genes related to inflammation and acute phase response 
(13).  After 4 weeks of carbon black NP inhalation, Sprague-Dawley rats were found to express 
increased pulmonary mRNA for the inflammatory cytokines interleukin-6 (IL-6) and monocyte 
chemotactic protein-1 (MCP-1), with elevated systolic blood pressure and circulating levels of 
the pro-inflammatory markers IL-6, MCP-1, and C-reactive protein (122).  These inflammatory 
cytokines have been linked to cardiovascular disease processes and may increase both cardiac 
and vascular inflammation(14; 56; 181).  Pulmonary exposure to NP could also result in 
autonomic dysregulation, which can also influence cardiovascular health effects.  NP could 
modulate autonomic regulation through the stimulation of vagal sensory nerves within the lung 
via direct interactions with NP or via inducible pulmonary inflammation similar to other forms of 
inhaled particulate matter (63; 98; 119).  This nerve stimulation could be exacerbated by NP 
compared to larger inhalable particles due to their potential to evade clearance mechanisms and 
possibly result in sustained level of pulmonary inflammation (42; 100).  These findings support 
the possible link between pulmonary NP exposure and subsequent and detrimental 
cardiovascular endpoints. 
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2.3. The era of engineered nanoparticles: tools to study the cardiovascular system 
Since their development, ENPuse in consumer goods, structural engineering components and 
electrothermal conductors has increased dramatically.  Research in ENP has also increased 
dramatically over the last two decades, as indicated by the number of publications on the carbon-
based NP, MWCNT and C60, in scientific journals (Figure 2.2).  ENP have been proposed for 
use in biomedical applications as antimicrobials, antivirals, drug delivery devices and contrast 
imaging agents.  While the unique physicochemical properties of ENP increase their 
applicability, they also raise concerns for potential adverse human exposure outcomes.  Despite 
apprehensions, the broad application of ENP has increased human exposures in occupational 
settings (74).  While dermal, oral/gastrointestinal, and inhalation exposures to NP are all relevant 
to the occupational setting, pulmonary exposures have been the principle route of NP 
administration in toxicological studies (124).  These investigations have shown that despite 
minimal pulmonary outcomes, in many cases, the cardiovascular system may be a key site of 
NP-induced toxicity (29; 95). 
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Figure 2.2 Research on carbon nanotubes and fullerenes has increased 
As the use of engineered nanoparticles expands across industry and medicine, research on these 
materials does as well.  (A) PubMed search results show that research has increased steadily over 
the last decade, but research on multi-walled carbon nanotubes (MWCNT) and associated 
toxicity make up a much smaller fraction of the search results.  (B) PubMed search results for 
fullerene shows a similar pattern but with 60-carbon fullerenes (C60) and associated toxicity 
make up a small fraction of the search results.   
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Elucidation of the cardiovascular derangements associated with pulmonary exposure to ENP has 
two potentially important benefits.  First, mechanisms of toxicity based on physicochemical 
characteristics of ENP couldsupport development of new or modified ENP with reduced 
cardiovascular-related toxicity.  Second, we may uncover mechanisms of cardiovascular toxicity 
in response to ENP that also underlie the elements of cardiovascular disease brought about by the 
exposure to NP fractions in air pollution.  While the emergence of ENP represents a relatively 
new paradigm in pulmonary exposure and cardiovascular risks in the occupational setting, 
pulmonary exposure to naturally occurring NP is not a novel paradigm.  Naturally occurring NP 
are produced in volcanic activity, forest/brush fires, weathering, formation from clay minerals, 
soil/rock erosion and dessert dust storms (149).  Thus, it makes sense that physiological systems 
have likely evolved mechanisms by which to respond to nano-sized environmental stimuli, i.e. 
NP.  
 
2.4. Engineered nanoparticles examined 
Two forms of carbon-based ENP have been selected for study in this dissertation: MWCNT and 
C60.  Both are comprised almost entirely of carbon, but despite having similar chemical make-
up, these two ENP have very different aspect ratios, which allow determination of how physical 
structure may impact the experimental endpoints. 
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2.4.1. Multi-walled carbon nanotubes 
MWCNT consist of multiple layers of graphite sheets rolled into concentrically arranged tubes 
(See Figure 2.3).  They can span microns in length but are only nanometers in diameter.  
MWCNT have extraordinary physicochemical characteristics that make them promising 
components in commercial goods (112).  Over the last two decades MWCNT have been 
incorporated into structural, electrical, and thermal engineering applications products.  The 
durability and capacity for electrothermal conduction makes MWCNT attractive for use in 
compact electronic devices (85; 86; 174).  Further, MWCNT are showing promise in many 
medical applications (133). 
 
As MWCNT use increases there is a greater need to understand thepotential physiological 
responses or any adverse endpoints following occupational or accidental inhalation (59).  For 
example, asbestos minerals presented many favorable physical properties that made them 
desirable for widespread use across industry, which was followed by the incorporation of 
asbestos into thousands of commercial products, and then unfortunately by the asbestos cancer 
epidemic (91; 92).  The same “incorporate before understanding physiological consequences” 
paradigm was also true for perfluorooctanoic acid, a component of Teflon (155).  Given that a 
complete assessment of biological responses to MWCNT exposure is lacking and the increasing 
probability of human interaction with MWCNT, there is concern that we may be repeating the 
“incorporate before understanding physiological consequences” history.  Rodent models have 
shown that pulmonary exposure to MWCNT elicits persistent lung inflammation (133), 
pulmonary fibrosis (107), and loss of lung function (173).  Cardiovascular endpoints following 
pulmonary exposure to MWCNT have also been investigated in a few cases and were found to 
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increase microvascular endothelial permeability via oxidative stress (129), diminish endothelial-
dependent relaxation in coronary resistance arterioles (153), enhance serum lipid peroxidation  
(137), diminish serum antioxidant capacity (137), and translocate from the lungs to the heart 
(153). 
 
 
 
 
 
 
Figure 2.3 The structure of a multi-walled carbon nanotube (120) 
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2.4.2. 60-carbon fullerene 
C60 is a spherical carbon allotrope first generated synthetically in 1985 but has likely been 
produced naturally in Earth’s environment for thousands of years, suggesting that human 
exposure to C60 is not necessarily a novel (See Figure 2.4) (6).  Synthetic production of C60 on 
a commercial scale has increased the probability of human exposures occupationally and 
potentially even environmentally (90).  The growing number of industrial and medical 
applications for C60 are not surprising due to its unique physicochemical properties (115).  The 
medicinal uses for C60 spur from its capacity to function as an antiviral, photosensitizer, 
antioxidant, drug/gene delivery device and contrast agent in diagnostic imaging (7).  C60 have 
been found in occupational environments at concentrations of 23,856 – 53,119 particles/L air 
(79).  Given the potential for humans to encounter C60, assessments of in vitro cytotoxicity (22; 
78), in vivo biodistribution (90; 156), biopersistence (146) and adverse pulmonary responses to 
C60 have been conducted (6; 114; 126; 145).  Despite the effort put into developing a 
toxicological profile for C60, the potential impacts of C60 on the cardiovascular system have 
rarely been examined. 
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Figure 2.4 Carbon organization of 60-carbon fullerene (151) 
  
20 
 
2.5. Pulmonary exposure models: intratracheal instillation vs. inhalation 
Two exposure models can be utilized to achieve exposure across the pulmonary interface: (i) 
intratracheal instillation and (ii) inhalation models.  Commentary on these models has been 
previously provided (154).  As it is used in this dissertation project, MWCNT or C60 are 
dispersed in an aqueous medium and delivered via a bolus droplet into the opening of the trachea 
of an anesthetized animal.  Upon inhalation the droplet is aerosolized and dispersed throughout 
the lung.  Instillation allows for ENP exposure mass to be easily reproduced and delivery of a 
particle mass into the lungs without ENP deposition in the nasal/upper airways.  Alternatively, 
the inhalation model is achieved by generating and incorporating ENP into an artificial 
atmosphere, allowing pulmonary deposition of ENP to occur during normal breathing while 
animals are unrestrained inside a whole body exposure chamber or restrained and exposed by a 
nose/head only device.  The inhalation model is the gold standard for pulmonary exposure 
models but inhalation facilities are expensive to setup, run, and maintain (43).  It is also difficult 
to determine exactly how much ENP exposure mass will be delivered into the lungs of each 
animal (177). 
 
2.6. Cardiac endpoints following nanoparticle exposure 
2.6.1. Cardiac ischemia and reperfusion injury 
In a real world scenario, individuals who experience a coronary artery occlusion (i.e. heart 
attack) will suffer ischemic injury in the zone of the myocardium distal to the occlusion, here 
after referred to as the zone at risk (ZAR).  During ischemia, loss of oxygen delivery to the 
myocardium stops mitochondrial oxidative phosphorylation in cardiac myocytes and 
subsequently loss of excitation contraction coupling (21).  If the ischemic event is not addressed, 
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cells within the ZAR are likely to undergo necrosis or apoptosis due to oxygen and nutrient 
deprivation, resulting in myocardial infarction.  In order to spare injury following a myocardial 
occlusion, catheterization of the occluded artery is performed and the ZAR is reperfused.  
Dependent upon the timing of intervention, myocardial reperfusion can limit the magnitude of 
infarction.  However, reperfusion generates complex deleterious reactions in the ZAR, which are 
collectively referred to as reperfusion injury (21; 106).  These reactions generated upon 
reperfusion include free radical production, Ca
2+
 loading and neutrophilia in the ZAR, which 
promote impaired cardiac function, arrhythmia and accelerated cell death in critically injured 
myocytes.  Both myocardial ischemic injury and reperfusion injury are referred to collectively as 
cardiac ischemia/reperfusion (I/R) injury (See Figure 2.5). 
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Figure 2.5 Ischemic injury compared to reperfusion injury in the heart (106) 
 
 
 
Cardiac I/R injury is complex.  The extent of myocardial infarction following I/R can depend 
upon several properties associated with organ and system levels of physiology.  One set of 
factors that contributes to, or results from, I/R injuryisintrinsic to the heart itself and includes 
electrical conductive properties of the heart, ventricular function, coronary resistance, and release 
of soluble factors that can impact heart function and coronary vascular resistance.  A second set 
of factors that can play an important role in cardiac I/R injury response isthe extrinsic factors, or 
systemic factors originating outside of the heart in the intact animal.  These include autonomic 
innervation/regulation of heart rate and contractility, and circulating endocrine and humoral 
factors.  In this study, two models of cardiac I/R injury were used to delineate between the role 
of intrinsic and extrinsic factors associated with expansion of I/R injury following NP exposure.  
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2.6.2. Cardiac ischemia/reperfusion – the in situ model 
One experimental model of cardiac I/R that accounts for the interplay of organ and system level 
factors is the in situ model.  In this model a stably anesthetized animal is intubated, ventilated 
under positive pressure, and subjected to a thoracotomy.  The left anterior descending coronary 
artery (LAD) is ligated for an ischemic period specified by the investigator and then the ligature 
is removed and the ZAR is allowed to reperfuse for a period of time (1; 87).  Cardiac I/R in situ 
has been described in large mammalian models, like pigs and dogs, and small mammalian 
models, like rabbits, guinea pigs, rats, and mice (70).  Large and small animal models exhibit 
differences in cardiac vulnerability to arrhythmia, especially lethal arrhythmia, with the 
incidence of I/R-induced arrhythmia being lower in hearts with smaller physical dimensions.  
This makes the rodent model of cardiac I/R an attractive choice to avoid unwanted animal losses 
that result from lethal arrhythmia when myocardial infarction is the desired endpoint.  Our 
laboratory has established an in situ model of cardiac I/R induced infarction in mice as a relevant 
endpoint in the study of pulmonary exposure to UFP (36), MWCNT (82; 165), and cerium oxide 
NP (176). 
 
2.6.3. Cardiac ischemia/reperfusion – the isolated Langendorff heart model 
The isolated Langendorff heart model provides a method of testing I/R injury unique from the in 
situ model.  In this model, the heart is isolated from the systemic vasculature, pulmonary system, 
and neurohumoral influences, allowing autoregulatory functions to be studied.  The heart is 
quickly removed from the animal and the aorta is cannulated for retrograde perfusion (1).  By 
delivering a heated and oxygenated physiological buffer in a retrograde fashion, the aortic valve 
is maintained in the closed position and the coronary ostia are perfused in a manner that can 
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sufficiently maintain the heart.  The isolated heart model was first established using frog hearts 
in 1866 by Elias Cyon, which was later modified for the isolated perfused mammalian heart by 
Oscar Langendorff in 1895 (183).  The perfusate in a Langendorff model can be delivered under 
constant flow with a peristaltic pump or under constant (hydrostatic) pressure using an elevated 
perfusate reservoir (147).  Changes in vascular resistance (∆R) can be indirectly measured in a 
Langendorff model by (i) measuring changes in perfusion pressure (∆P) in the constant flow (Q) 
model and (ii) by changes in perfusion flow (∆Q) in the constant pressure (P) model using the 
following equation: 
Constant Flow Model: ∆R = Q • ∆P 
Constant Pressure Model: ∆R = P/∆Q 
The Langendorff apparatus can also be outfitted to measure volume conducted electrocardiogram 
(ECG) and left ventricular developed pressure (LVDP) by placing a pressurized balloon inside 
the left ventricle (1; 180).  The ischemic episode can be conducted regionally by ligature of the 
LAD or globally by shutting off total perfusion to the isolated heart.  Reperfusion is then 
allowed, either by removal of the ligature or continuation of global perfusion (1). 
 
The isolated heart technique eliminates systemic factors during cardiac I/R, but it is important to 
identify the practical purposes, benefits, and limitations of using a simplified approach, so as not 
to over interpret the results.  For example, myocardial infarction in response to in situ cardiac I/R 
may be exacerbated 24 hours following an acute pulmonary exposure to ENP.  It is possible that 
during the 24 hour period following the pulmonary exposure prior to I/R, changes could have 
occurred in coronary arteries that promote impaired reperfusion.  This parameter cannot be 
monitored easily in the in situ model of I/R.  However, by using an isolated heart model, aberrant 
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reperfusion flow can be described and thus lead to more well informed hypotheses of cardiac I/R 
injury mechanisms. 
 
2.6.4. Engineered nanoparticle exposure and the heart 
Despite the absolute vitality of the heart in the cardiovascular system and the overwhelming 
prevalence of heart disease, only a few studies have examined changes in heart function or 
alterations in cardiac injury in response to I/R induced by ENP.  One experiment showed that 
direct delivery of TiO2, SiO2, or Printex90 NP in the perfusate of an isolated Langendorff guinea 
pig heart model, the NP induced tachycardia, compensatory coronary flow, arrhythmia, ST 
elevation, and atrioventricular block (152).  Pulmonary exposure to ENP can also alter I/R injury 
in a Langendorff heart model.  Specifically, acid functionalized single-walled carbon nanotubes 
(SWCNT) were intratracheally instilled 24 hours prior to heart isolation and I/R (162).  They 
conducted 20/120 minutes of I/R, respectively, and found decreased LVDP during reperfusion 
and expansion of post-I/R myocardial infarction.  Work from our own group has demonstrated 
20/120 minutes of cardiac I/R in situ expands myocardial infarction in mice 24 hours after 
intratracheal instillation of  CeO2 (176) or MWCNT (165).  
 
One study examined the ability of ENP exposure to influence autonomic regulation of the heart 
and found that multiple intratracheal instillations of SWCNT in rats decreased heart rate and 
increased in baroreflex sequences (98).  These findings suggested that baroreflex function might 
have been impaired due to a loss of arterial pressure sensitivity.  Such derangements are 
prognostic for cardiac mortality, perhaps to a greater extent in individuals with ischemic 
cardiomyopathy and myocardial infarction (93). 
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2.7. Arterial endpoints following nanoparticle exposure  
2.7.1 The vascular system 
The vascular system is generally known for oxygen/nutrient delivery and waste removal from 
tissue.  It also plays an important role in the homeostasis of mean arterial pressure, hemostasis, 
blood coagulation, immunity, inflammation, humoral propagation, fluid/ion balance, 
angiogenesis, and thermoregulation.  The vascular system is arranged into conduit arteries, 
resistance arteries, arterioles, capillaries, venules and veins.  In terms of cellular components, the 
vascular system is comprised of vascular endothelial cells, vascular smooth muscle cells, 
autonomic nerve endings, resident mast cells, macrophages, circulating neutrophils, monocytes, 
perivascular fat, connective tissues, and extracellular matrices.  These components assert the 
complex mechanisms regulating physiological vascular function and can potentially be 
influenced by NP exposure through direct NP-cell interactions, autonomic dysfunction, and the 
release of paracrine and autocrinemediators. 
 
Vascular endothelial cells (EC) make up the thin cellular monolayer that lines the entire 
vasculature.  The human vasculature contains approximately 60 trillion EC, which execute many 
physiological functions that include influences on vascular reactivity, recruitment and adherence 
of leukocytes, innate and adaptive immune function, and modulation of vascular permeability 
(2).  EC can influence vascular reactivity by first detecting local or systemic signals and then 
releasing endothelial derived relaxing or contracting factors that act in a paracrine fashion to 
elicit vascular smooth muscle-mediated changes in arterial diameter.  Endothelial function is 
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often tested by evaluating acetylcholine (ACh)-mediated vasorelaxation, in contrast to a 
vasorelaxation response stimulated by a NO donor like sodium nitroprusside (SNP). 
 
Nonstriated vascular smooth muscle cells (VSMC) make up the medial wall of arteries and 
arterioles.  They contain the primary machinery by which arteries and arterioles modulate 
changes in vessel diameter.  Under resting conditions the state of VSMC contraction is referred 
to vascular tone.  Tonic contraction of VSMC maintains vessel shape and allows vessels to 
withstand blood pressure.  Vascular tone can be contrasted with the term vascular reactivity, 
which describes the ability of a blood vessel to sense physical or chemical stimuli, and respond 
by dilating or constricting appropriately.  This is necessary to maintain tissue homeostasis 
despite changes in the physiological environment. VSMC can sense chemical ligands released 
locally by autocrine/paracrine mechanisms or systemically by the endocrine and/or autonomic 
nervous system.  VSMC can also develop myogenic responses to changes in transmural pressure 
(stretch) and changes in wall tension.  VSMC contraction or relaxation is primarily driven by 
changes in intracellular Ca
2+
 concentration, but can also be regulated by changing the Ca
2+
 
sensitivity of the VSMC contractile apparatus (73; 150).  In contrast to skeletal muscle, VSMC 
contraction is a response of Ca
2+
 on myosin rather than a response of Ca
2+
 on actin (175).  
Similar to skeletal muscle a VSMC can undergo concentric and isometric contractions.  
However, unlike skeletal muscle, VSMC do not undergo eccentric contractions, but do show a 
nominal property of length-dependence in their contractile responses. 
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2.7.2. Physiological parameters regulated by arteries 
From a fundamental functional standpoint, arteries, resistance arteries and arterioles are critical 
to match the supply of blood to the demand for blood in an organ or tissue.  Change in metabolic 
demand within an organ/tissue initiates vasoactive signals to the arterial system and the arterial 
system itself modulates blood flow to an organ/tissue by changing vascular resistance through 
the regulation of arterial wall tension.  For example during exercise, increased oxygen 
consumption in skeletal muscle increases global oxygen demand and results in increased heart 
rate and cardiac output.  As heart rate increases, oxygen demand in the heart increases. This is 
met almost immediately by an increase in coronary blood flow.  The increase in coronary blood 
flow is partly related to an increase in mean arterial pressure (driving force), but is due in large 
part to a decrease in vascular resistance to flow, i.e. vasodilation (46).  Total vascular resistance 
is the sum of passive and active vascular resistance.  Passive vascular resistance is that associated 
with structural components of an artery and active resistance is that associated with VSMC 
contraction. 
 
Aside from increased metabolic demand, arteries, resistance arteries, and arterioles can 
autoregulate the maintenance of constant blood flow to an organ in the face of changing 
perfusion pressure.  As transmural pressure (Pi) increases, arteries distend and then respond by 
vasoconstricting, decreasing lumen diameter (2r) and increasing vascular resistance to flow.  The 
opposite also occurs.  As Pi decreases, arteries deflate and respond by vasodilating, increasing 
lumen diameter and decreasing vascular resistance to flow.  The Law of Laplace asserts that 
these phenomena, termed myogenic responses, act to regulate wall tension: 
Law of Laplace: Wall tension = Pi • r 
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Schubert and Mulvany have reviewed myogenic responses and provide commentary on several 
mechanisms that may regulate myogenic responses (141).  Schubert described the potential 
mechanisms that possibly initiate the myogenic response as interplay between VSMC membrane 
depolarization, increase in intracellular Ca
2+
 concentration, and activation of intracellular second 
messenger systems. 
 
2.7.3. Isolated artery techniques 
This dissertation project utilizes wire myography of LAD segments isolated from rats in order to 
assess changes in coronary artery VSMC force generating capacity after pulmonary exposures to 
ENP.  Wire myography of arterial segments was first developed and reported in Nature in 1976 
by Michael Mulvany and William Halpern (117).  In this technique, as used in this dissertation, 
LAD segments 0.5 – 2 mm in length were resected from the surrounding cardiac tissue and two 
40 m diameter stainless steel wires were passed through the lumen.  The LAD segments were 
then mounted into a chamber from a DMT 610M myograph chamber (DMT, Inc., Ann Arbor 
MI, USA) by attaching one wire to an adjustable micrometer and the second was attached to a 
force transducer.  The technique was developed to assess isometric force development in VSMC 
at an arterial wall tension and internal circumference selected by the investigator (117).  The 
experiments conducted by Mulvany and Halpern demonstrated that (i) the VSMC within an 
arterial preparation were oriented to contract across the diameter of the artery examined, within 
the vector of the force transducer and (ii) the length of any selected individual VSMC within an 
arterial preparation always occupied a fixed proportion of the internal circumference of that 
artery.  Mulvany and Halpern interpreted these findings to mean that active force data collected 
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from arteries on a wire myograph represented the force generating capacities of the individual 
VSMC in situ. 
 
The wire myography technique can be contrasted against another experimental isolated artery 
technique called pressure myography.  Even though pressure myography is not utilized in this 
dissertation, due to its importance in the study of vascular physiology, a brief review of pressure 
myography is provided.  Isolated perfused and pressurized small arteries (50 - 250 µm in 
diameter) was, perhaps, first described by Uchida et al. and published in Circulation Research in 
1967 (164).  The pressure myography technique for small arteries (5 - 100 µm in diameter), as it 
is used today, was described by Duling et al. and published in American Journal of Physiology, 
Heart and Circulatory Physiology in 1981 (45).  In short, small resistance artery segments are 
resected from the vascular bed of interest and cannulated on both ends so that intramural 
pressure can be controlled by the investigator, and changes in diameter are monitored 
microscopically (116).  Pressure myography is an important tool in the field of vascular 
physiology because it allows the artery being examined to regulate arterial wall tension.  The 
primary endpoint for isolated arteries on a pressure myograph is visual assessment of change in 
diameter. 
 
Aside from the endpoints measured, the physical conditions utilized to functionally assess 
VSMC are different between wire myography and pressure myography.  A wire myograph 
measures the change in smooth muscle force (∆Ftotal = ∆Fpassive + ∆Factive) under isometric 
conditions to derive ∆F/mm (i.e. tension).  A pressure myograph measures change in distance 
(∆D) per constant internal pressure (i.e. opposing force) to derive ∆D/mmHg.  Alternatively, the 
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pressure myograph can be used to mimic isometric contractions by increasing the internal 
pressure during a contraction in order to maintain the initial lumen diameter.  Therefore, internal 
pressure utilized to distend an arterial segment on a pressure myograph can be considered 
synonymous with the passive force required to passively stretch an arterial segment on a wire 
myograph.  That being considered, one key similarity between the two techniques is the 
relationship between ∆internal pressure and ∆passive internal diameter based on the Law of 
Laplace (23).  In other words the change in passive pressure required to displace passive 
diameter is similar in both preparations.  This highlights an important difference between the 
wire myograph and the pressure myograph technique.  That difference is the difference in the 
shape and slope of active tension curves generated when length-tension relationships have been 
established.  The active tension curve of an arterial length-tension relationship established by 
wire myography has a broader base, steeper ascending slope and a broader peak in relation to the 
optimal arterial diameter (182) than the active tension curve established using a pressure 
myograph, which has a narrower base, flatter ascending slope and narrower peak (35; 38).  
Thesedifferences are depicted in Figure 2.6, though it should be noted that the data presented are 
derived from two different vascular beds, from two different species, and were primarily of two 
different diameters (38; 182).  The differences in species, vascular bed and artery diameter are 
likely of minimal concern since Davis reported that active tension curves were similar in shape 
across 4 different orders of arterial branches from hamster cheek pouch arteries using pressure 
myography (38) and Cox has reported the same shape of active tension curves from 3 different 
canine hind limb arterial beds, of 3 different sizes (35).   
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Given that active tension (TA) curves are derived by subtracting passive tension (TP) from total 
tension (TT) it may seem logical to assume that the passive tension curve may be responsible for 
the difference in derived active tension. 
TA = TT - TP 
It is important to note that because the relative thickness of the medial wall increases as artery 
size decreases, the relative amount of connective tissue in an artery is proportional to the relative 
wall thickness of the artery (12).  This is important because the connective tissue is responsible 
for passive element of VSMC length-tension curves (175).  However, as stated previously, 
passive tension curves have been reported to be nearly identical between arteries assessed via 
wire myography and arteries assessed via pressure myography (23).  Thus, the difference in the 
active properties of VSMC can be impacted by the in vitro conditions used to assess their 
mechanical function.  In that regard, caution should be used when interpreting data derived from 
active stress generation in arterial preparations via wire myography.  
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Figure 2.6 Arterial active length-tension shape depends on technique(38; 182) 
Length tension-relationship in small arteries can be assessed via (A) wire myography and (B) 
pressure myography.  The closed squares indicate total/activated response and open squares 
indicate the passive/inactivated response.  The dashed line indicates the active tension response 
derived by subtracting passive/inactivated response from the total/activated response, which 
reveals a fundamental difference in the shape and slope to the active tension curve between the 
two techniques. 
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Another difference between the techniques is that pharmacological assessment of arteries on a 
pressure myograph yield lower threshold values and EC50 values than pharmacological 
assessment of arteries on a wire myograph.  Arteries pharmacologically assessed on a wire 
myograph have steeper Hillslope values than arteries pharmacologically assessed on a pressure 
myograph (23).  This highlights another area in which care should be used in the interpretation of 
pharmacological data generated from arterial preparations on a wire myograph.  
 
Despite the apparent strengths of the pressure myograph approach in vascular physiology, 
including the use of much more physiologically relevant conditions, it does have a few 
limitations for examination of VSMC force generating capacity.  Maximal VSMC activation can 
be problematic due to complete closure of the arterial lumen which is difficult to reverse (38; 
182).  Also, due to VSMC shortening, deactivation of the contractile apparatus can occur and 
cause underestimation of maximal stress generating capacity (38; 182).  Therefore, wire 
myography is an ideal technique for mechanical arterial studies assessing VSMC stress 
generating capacity under isometric conditions.  However, VSMC contraction/relaxation 
response profiles obtained under isometric conditions could be due to mechanisms that have less 
important roles in vivo, and careful interpretation of data generated via wire myography is 
critical (23). 
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2.7.4. Nanoparticle exposure and arteries 
Reviews on mechanisms of NP-induced toxicities have described the ability of NP to induce 
inflammation which can disrupt vascular function (74; 144).  Given that the walls of conduit 
arteries contain microvessel networks that can intensely regulate vascular inflammation (135), 
assessment of conduit artery function may be important following NP exposure.  We have 
reported that aortic vascular smooth muscle contraction in response to adenosine was altered 24 
hrs following pulmonary instillation of 10 µg and 30 µg of CeO2 in mice (176).  Diminished 
endothelial-dependent smooth muscle relaxation responses to ACh in isolated aortic segments 
has also been documented after carbon black NP instillation in mice, in the absence of altered 
SNP responsiveness (168).  Pulmonary exposure to NP may also disrupt smaller conduit artery 
function.  Wire myography analysis of carotid artery segments isolated from mice previously 
exposed to varying concentrations of Ni(OH)2 nanoparticles (NH-NP) via whole body inhalation 
chambers for 1, 3, or 5 days (5 hrs/day) showed impaired PE and ACh vasomotor responses in 
both a NP dose- and time-dependent fashion (37). 
 
Arterioles provide the largest resistance to blood flow in the vasculature and regulate tissue 
specific flow, thus the response of arterioles to NP exposure is an important area of research.  
Inhalation-mediated lung deposition of 10 µg of TiO2 in rats was found to be capable of 
generating endothelial dysfunction in subepicardial arterioles and increasing heart weight 
potentially through increased vascular permeability (95).  They also suggest inhalation of TiO2 
disrupted microvascular NO bioavailability, and increased oxidative and nitrosative stress in 
arteriolar walls of the systemic vasculature (123).  In other reported studies, endothelium-
dependent dilation responses to ACh and the Ca
2+
 ionophore A23187 were both found to be 
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impaired via pressure myography of coronary and mesenteric arterioles isolated from rats 
previously exposed to inhalation of MWCNT (153) or intratracheal instillation CeO2 (111).  
 
While many effects of NP exposure have been associated with endothelium-dependent 
mechanisms, arteriolar function may also be disrupted following NP exposure via endothelium-
independent mechanisms.  In one case arterioles of the spinotrapezious muscle were examined 
by intravital microscopy following TiO2 NP inhalation in rats (88).  In this study arterioles 
demonstrated heightened sensitivity to α-adrenergic blockade during perivascular nerve 
stimulation and blunted arteriolar dilation in response to active hyperemia.  The dampened active 
hyperemia-mediated dilation was not exacerbated by the use of a NO synthase inhibitor, 
suggesting a loss of NO bioavailability.  However, COX inhibition did further impair active 
hyperemia-induced vasodilation, suggesting that arterioles from the TiO2 exposed animals had 
compensated for the reduced NO bioavailability by a COX-mediated mechanism.  In a different 
study that examined CeO2 instillation, endothelium-independent vasodilation responses to SNP 
and spermine NONOate were also found to be impaired in coronary arterioles on a pressure 
myograph (111). 
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2.8. Key pathways and cardiac/vascular ligands examined 
2.8.1. Endothelin-1 
ET-1 is a dynamic autocrine/paracrine signaling agent involved in the maintenance of many 
physiological functions and is one of the most potent endogenous vasoconstrictor currently 
identified (121).  ET-1 is a 21 amino acid peptide released from many cell types, including EC, 
VSMC and cardiac myocytes (84).  ET-1 interacts with two receptor subtypes, endothelin A 
receptors (ETAR) and endothelin B receptors (ETBR).  VSMC express both ETAR and ETBR 
receptors, which are G protein-coupled receptors coupled to Gαq.  Activation of ETAR or ETBR 
on VSMC triggers the liberation of inositol triphosphate and diacylglycerol from the cell 
membrane, causing an increase in intracellular Ca
2+
 concentration and subsequent 
vasoconstriction.  Vascular EC express ETBR receptors that promote vasodilation through the 
release of NO (131).  In the coronary circulation low concentrations of ET-1 promote 
vasodilation and enhanced coronary flow but at higher concentrations ET-1 produces strong 
vasoconstriction and reduction of coronary flow (121).  ET-1 is arrhythmogenic in cardiac tissue 
(47) and is also released from the isolated hearts during I/R (19).  Given that ET-1 mechanisms 
have been linked to particulate matter exposure and cardiac ischemic injury (80), perhaps ET-1 is 
an important target following pulmonary exposure to ENP. 
 
2.8.2. Thromboxane and the cyclooxygenase pathway 
TXA2 is an eicosanoid produced by the cyclooxygenase (COX) pathway that is involved in 
vasoconstriction and platelet aggregation (53).  In cells, COX converts free arachidonic acid into 
prostaglandin H2 which is then converted into TXA2 by TXA2 synthetase (TXS)(52).  VSMC 
contraction occurs when TXA2 activates TXA2 receptor (TP), which is a G protein-coupled 
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receptor that acts through release of inositol triphosphate and diacylglycerol to promote 
intracellular Ca
2+
 release.  Activation of TP on vascular endothelial cells can stimulate a Rho-
kinase-dependent depression of NO release (101), which can potentiate vasoconstriction.  Such a 
loss in NO bioavailability may feed-forward to exacerbate TXA2-mediated vasoconstriction by 
enhancing TXA2 release (52), given that NO-mediated inhibition of TXS has been documented 
(170).  TXA2 is an ideal autocrine/paracrine agent because it has a ~30 second half-life and is 
rapidly hydrolyzed to the inactive thromboxane B2 (TXB2) form (97), thus it must act locally.  
TXA2 is heavily involved in platelet activation, thrombus formation and vasoconstriction and 
has been identified as an important marker of acute coronary syndromes, like unstable angina 
and myocardial infarction (54).  TXA2 has further been linked to cardiac ischemic injury and 
arrhythmia (34).  Given that MWCNT have been shown to activate platelets via increased TXA2 
release (65), perhaps TXA2 may contribute to cardiovascular consequences following ENP 
exposure in general. 
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2.9. Conclusion of literature review 
The recognition that particulate matter exposure is animportantrisk factor for heart disease has 
generated concern that occupational exposure to ENP may also have cardiovascular 
consequences.  If the expectation that particle toxicity increases as particle size decreases on an 
equal mass basis is true, then it is important to improve our understanding of how pulmonary 
exposure to ENP may contribute to cardiovascular derangements.  Since naturally occurring NP 
have always been present in the environment, mammals have likely evolved physiological 
mechanisms to respond to such stimuli.  This dissertation project proposed to (i) investigate 
mechanisms responsible for cardiovascular detriments associated with pulmonary exposure to 
ENP and (ii) identify key cardiovascular endpoints that can potentially be used to screen ENP for 
cardiotoxic responses in order to protect individuals in the occupational setting.  Specifically 
MWCNT have been shown to increase cardiac I/R injury 24 hours following exposure (165), 
similar to previous studies of ultrafine particulate matter (36).  However, the question remains, 
how does ENP exposure lead to expansion of myocardial infarction followingI/R?  Many 
investigations have utilized a lungs-forward approach to uncovering the mechanisms of 
cardiovascular toxicity in response to pulmonary NP exposure.  Here we propose to work back 
from the heart following pulmonary exposure to ENP in order to better understand any 
derangements inherent to the heart itself, or the coronary vasculature.  After doing so we believe 
we can more clearly hypothesize the mechanisms that caused the derangements.  Of the many 
proposed mechanisms potentially responsible for cardiovascular derangements following 
pulmonary exposure to NP, ET-1 and TXA2 could contribute to cardiac arrhythmia and 
enhanced coronary artery contraction, ultimately exacerbating cardiac I/R injury.
CHAPTER 3 
INTRATRACHEAL INSTILLATION OF MULTI-WALLED CARBON NANOTUBES 
EXACERBATES CARDIAC ISCHEMIA/REPERFUSION INJURY AND DEPRESSES 
CORONARY REPERFUSION FLOW 
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3.1. Introduction 
Over the last two decades, structural, electrical, and thermal engineering has been enhanced with 
the development of MWCNT.  These materials are layers of graphite sheets rolled into 
concentrically arranged tubes that span microns in length but only nanometers in diameter (128).  
MWCNT have extraordinary physicochemical properties and versatility that have made them 
promising materials to improve many modern goods (112).  Their durability and capacity for 
electrothermal conduction makes them attractive for use in compact electronic devices (85; 86; 
174), and MWCNT are showing promise in many medical applications (133).  With the 
increasing use of MWCNT comes a greater need to understand the potential consequences of 
occupational inhalation and the resulting physiological responses (59).  In rodent models, 
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pulmonary responses to MWCNT include persistent lung inflammation (133), pulmonary 
fibrosis (107), and loss of lung function (173).  Cardiovascular endpoints are far less studied 
following pulmonary exposure to MWCNT, but a few studies have demonstrated that MWCNT 
exposure canresult in translocation from the lung to the heart (153), increase microvascular 
endothelial permeability via oxidative stress (129), enhance serum lipid peroxidation (137), and 
diminish serum antioxidant capacity (137).  It is reasonable to closely examine cardiovascular 
endpoints following MWCNT exposure because deleterious cardiovascular consequences have 
been shown to result from pulmonary exposure to other nanomaterials and particulates.  Those 
consequences have been linked to oxidative stress (28; 36; 95), systemic inflammation (176), 
and/or altered endothelin signaling (30; 31). 
 
The isolated Langendorff heart model has been used to examine cardiovascular endpoints 
following nanoparticle exposure (152) and has also been used to assess changes in cardiac 
electrophysiology and ischemia/reperfusion (I/R) injury, in responses to various chemical 
compounds and pathological conditions (9; 147).  ET-1 is a key autocrine/paracrine mediator 
during myocardial I/R due to its arrhythmogenic properties (47) and its vasoconstrictive effect, 
which impairs reperfusion flow (131).  ET-1 is released during reperfusion in hearts subjected to 
I/R injury (19) and both endogenous and exogenous ET-1 has been shown to contribute to infarct 
expansion during cardiac I/R (127).  Thromboxane (TXA2) is another autocrine/paracrine agent 
thathas been linked to cardiac ischemic injury and arrhythmia (34).  TXA2 is heavily involved in 
platelet activation, thrombus formation and vasoconstriction and has been identified as an 
important marker of acute coronary syndromes, like unstable angina and myocardial infarction 
(54).  MWCNT have also been shown to directly activate platelets via increased TXA2 release 
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(65).  Collectively, perhaps ET-1 and TXA2 are important ligands to study following pulmonary 
exposure to MWCNT and myocardial infarction. 
 
The impacts of MWCNT exposure in vivo on isolated heart function and I/R injury have not been 
investigated. The purpose of this study was to investigate baseline isolated heart function and 
cardiac I/R injury 24 hours after pulmonary exposure to MWCNTin vivo.  Specifically, we tested 
the hypothesis that intratracheal instillation of MWCNT would enhance the release of ET-1 and 
TXA2 during reperfusion and impair coronary reperfusion flow and result in the expansion of 
myocardial infarction following I/R.  
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3.2. Materials and Methods 
3.2.1. Multi-walled carbon nanotubes and vehicle 
Vehicle instillate (10% surfactant/saline): Solution by volume is 90% sterile saline (0.9 % NaCl) 
and 10% pulmonary surfactant (Infasurf™, a gift from ONY, Inc., Amherst, NY).  Infasurf™ 
contains: (per mL of 0.9% NaCl solution) 35 mg total bovine phospholipids, of which 16 mg are 
disaturated phosphatidylcholine, and 0.7 mg bovine proteins, of which 0.44 mg are hydrophobic 
surfactant-associated protein C and 0.26 mg are hydrophobic surfactant-associated protein B 
(http://www.infasurf.com/about-infasurf/#composition). 
 
MWCNT instillate:  MWCNT were provided by NanoTechLabs, Inc. (Yadkinville, NC, USA).  
For 100 µg dosing suspensions, MWCNT were added to the vehicle instillate to a concentration 
of 0.5 mg/mL.  For 10 µg and 1 µg dosing solutions, 1:10 serial dilutions were performed with 
vehicle instillate.  Immediately prior to instillation MWCNT suspensions were sonicated in a 
cup-horn sonicator (Qsonica, LLC - Newton, CT, USA) for 2 minutes at 65% amplitude to reach 
and approximate energy output of 10,800 J. 
 
3.2.2. Hydrodynamic size and zeta potential 
The MWCNT and suspensions used in this study were characterized previously (173).  MWCNT 
were analyzed in 10%SS suspensions for hydrodynamic size by dynamic light scattering using a 
Nanosizer S90 (Malvern Instruments, Worcestershire, UK) and zeta potential was determined 
using a Zeta ZS (Malvern Instruments).  
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3.2.3. Particle number assessment 
MWCNT particle numbers were analyzed in solution by counting events in 10 µl of sample 
using a BD Accuri C6 flow cytometer (BD, San Jose CA, USA).  Briefly samples were prepared 
as described above.   Each sample was run through the flow cytometer to collect a total of 10 µl 
and analyzed for total events using BD Accuri C6 software with background events subtracted.  
Samples were analyzed on 3-4 separate runs with a cleaning cycle run between each sample 
measurement.  Each measurement was multiplied by 20 to obtain the particle number delivered 
to each rat (10 µL x 20 = 200 µL).  The mean of the triplicate measurement is reported. 
 
3.2.4. Animals 
Male Sprague-Dawley rats were purchased from Charles River (Morrisville, NC, USA).  Rats 
were 10-12 weeks of age at the time of purchase and housed in the Department of Comparative 
Medicine at East Carolina University.  Each rat had access to standard laboratory chow and 
water ad libitum in a temperature regulated facility (23 ± 1°C) under 12:12 hour light-dark 
cycles.  We provided each rat with a minimum of 5 days to acclimate prior to experimental 
manipulations.  All use of rats in this study complied with protocols approved by the East 
Carolina University Institutional Animal Care and Use Committee. 
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3.2.5. Instillations 
One day prior to sacrifice, rats were anesthetized with Isoflurane.  A bolus of 1, 10, or 100 µg of 
MWCNT suspended in 200 µl of vehicle, or vehicle only (200 µl) was delivered into the opening 
of the trachea using a micro-pipette.  Rats were monitored until normal grooming habits 
resumed. 
 
3.2.6. Cardiac ischemia/reperfusion protocol 
One day following MWCNT or vehicle instillations, rats were anesthetized with an 
intraperitoneal injection of ketamine/xylazine (85/15 mg/kg, respectively).  After reflexes 
subsided, hearts were excised and mounted onto a modified Langendorff apparatus utilizing 
aortic retrograde perfusion under constant pressure (75 mmHg), without electrical pacing, as 
previously described (57).  Perfusion buffer contained (mM) 118 NaCl, 24 NaHCO3, 1.2 
KH2PO4, 4.75 KCl, 1.2 MgSO4, 2.0 CaCl2, and 10 glucose (equilibrated with 95/5 % O2/CO2), 
heated to 37°C, as previously described (17; 57).  After 5 minutes of stable parameter recordings 
established a baseline, hearts were challenged with 20 minutes of global ischemia and then 
reperfused for 120 minutes.  Reported data for ECG, left ventricular developed pressure (LVDP) 
and coronary flow rate were recorded throughout the each experiment using a PowerLab 
interface (ADInstruments, Inc., Colorado Springs, CO) and LabChart software (ADInstruments, 
Inc.).  Premature ventricular contractions (PVC) were counted during the stable baseline 
period.Cardiac arrhythmia was scored during the 2 hour reperfusion period as previously 
described (57).  Coronary flow rate was digitally monitored in real time using a flow probe 
(Transonic Systems, Ithaca, NY) connected in series with the perfusion cannula.  Raw flow rates 
were normalized to the wet weight of the corresponding heart.  The wet weight of each heart was 
obtained immediately after the end of the perfusion protocol.  Though wet:dry weight ratios were 
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not collected in this study, there is no evidence of marked edema formation in our model, with 
wet:dry ratios normally ranging between 75-78%.  Afterwards hearts were serially sectioned and 
incubated in a 1% triphenyltetrazolium chloride/0.9% NaCl solution for the determination of 
infarct size, as described previously (17; 148).  
 
3.2.7. Endothelin-1 and thromboxane in the coronary effluent 
During I/R experiments the vena cava were occluded and coronary effluent was collected by 
cannulating the pulmonary artery.  Effluent samples (4-5 mL) were collected from the vehicle 
and 100 µg MWCNT groups at baseline, at the onset of reperfusion (0 min), at 5 min, and at 10 
min into reperfusion (samples collected for approximately 30-50 sec at each time-point).  
Effluent samples were snap-frozen in liquid nitrogen and stored at -80°C until analysis.  An ET-1 
enzyme immunoassay plate (ADI-900-020A, Enzo Life Sciences, Farmingdale, NY) was used to 
determine ET-1 levels in the coronary effluent samples, per the manufacturer’s instructions.  
Optical densities were determined with a plate reader (Synergy HT, BioTek Instruments, 
Winooski, VT) using Gen5 software.  The assay detection limit for conversion to ET-1 
concentration occurred at optical densities of 0.098, corresponding to 0.1 pg/ml.  Optical 
densities <0.098 were taken as 0 pg/ml.  ET-1 concentrations were then normalized per gram of 
the corresponding wet heart weight (pg/mL/g of tissue).  Since TXA2 is rapidly hydrolyzed to 
TXB2, a TXB2 ELISA (ADI-900-002, Enzo Life Sciences) was used to quantifyTXA2 release 
from isolated hearts into the coronary effluents.  TXB2 concentrations were normalized per gram 
of the corresponding wet heart weight (pg/mL/g of tissue). 
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3.2.8. Statistics 
All data are reported as mean ± SEM.  Graphpad Prism software (version 5, LaJolla, CA) was 
used to conduct statistical analyses.  A Student’s t-test was performed to determine statistical 
significance against vehicle data for premature ventricular contractions, ending left ventricular 
pressure, infarct size, coronary flow, and ET-1 concentration in coronary effluent during 
reperfusion.  
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3.3. Results 
3.3.1. Multi-walled carbon nanotube physical characteristics 
The MWCNT suspension characteristics are reported in Table 3.1.  Hydrodynamic sizes were 
found in a bimodal distribution. The major peak occurred at particle sizes of 200 nm and a 
smaller peak occurred at particle sizes of approximately 1000 nm.  The zeta potential of the 
MWCNT suspension was determined to be -44.6 mV indicating that the MWCNT were stably 
dispersed in the 10% surfactant/saline.  Flowcytometry analysis of10 L of 0.5 mg/mL MWCNT 
suspension showed a particle count of 37,147 ± 625 particles.  The surface area was 
approximated to be 655 m2 per 10 L of 0.5 mg/mL MWCNT suspension based on the 
MWCNT characterization in a previous study (173). 
 
Table 3.1 Multi-walled carbon nanotube particle characterization 
Physical characterization of  MWCNT suspensions (mean ± SEM) 
Hydrodynamic size, nm 200 ± 50, 1000 ± 150 
Zeta potential -44.6 mV 
0.5 mg/mL suspension particle number (per per 10 µL) 37,147 ± 625 
Calculated surface area of 0.5 mg/mL suspension (per 10 µL) 23.4 mm
2
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3.3.2. Baseline recordings from isolated hearts 
Baseline measurements for ECG, PVC, coronary flow, ET-1 concentration, and TXB2 
concentration are shown in Figure 3.1. These data indicate that MWCNT exposure increased 
aberrant ECG tracing as depicted by representative ECG tracings taken from the 5 minute 
baseline periods (Figure 3.1A).  The mean total number of premature ventricular contractions 
counted during baseline recordings was also elevated significantly in the 10 g and 100 g 
MWCNT groups compared to the vehicle and 1 g MWCNT groups (Figure 3.1B).  The mean 
minute coronary flow rate (Figure 3.1C) and mean total coronary flow (Figure 3.1D) were not 
significantly different between groups during baseline recordings.  ET-1 concentrations 
measured in coronary effluents collected at baseline were below detectable limits in the 100 g 
and vehicle groups (Figure 3.1E).  TXB2 concentrations in coronary effluents collected at 
baseline were slightly elevated (P = 0.06) in the 100 g MWCNT group compared to the vehicle 
group (Figure 3.1F). 
 
Figure 3.1 Increased premature ventricular contractions at baseline in isolated hearts 
MWCNT exposure increased aberrant ECG and PVC in isolated rat hearts at baseline.  (A) 
Representative ECG tracings taken from baseline.  (B) Number of premature ventricular 
contractions counted during baseline.  (C) Minute coronary flow rate for each group during 
baseline recordings.  (D) Total coronary flow during baseline recording.  (E) ET-1 
concentrations measured in coronary effluents collected at baseline (below detectable limits).  
(F) TXB2 concentrations measured in coronary effluents collected at baseline.  Data are mean ± 
SEM. *P < 0.05. 
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3.3.3. Coronary reperfusion flow and concentrations of endothelin-1 and thromboxane B2 
in effluent 
Coronary flow and ET-1/TXB2 data are shown in Figure 3.2.  Coronary flow was depressed by 
~30% (P < 0.05) during the first 30 min of reperfusion in isolated hearts from rats instilled with 
100 µg MWCNT compared to those from rats instilled with the vehicle (Figures 3.2A and 
3.2B).The mean ET-1 concentrations in coronary effluent during early reperfusion were 
increased (P < 0.05) in the 100 g MWCNT group compared to the vehicle group (Figure 3.2C).  
The mean TXB2 concentrations in coronary effluent during early reperfusion were also slightly 
elevated (P = 0.06) in the 100 g MWCNT group compared to the vehicle group (Figure 3.2D). 
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Figure 3.2 Coronary reperfusion flow and effluent endothelin-1 and thromboxane B2 
MWCNT exposure promoted early reperfusion depressions in coronary flow and increased ET-1 
release.  (A) Mean coronary perfusion flow tracing for vehicle and 100 g MWCNT.  (B) Total 
coronary flow during 30 minute window identified in panel A, flow for 10 g and 1 g MWCNT 
also provided.  (C) ET-1 concentration in effluents collected during early reperfusion (first 15 
minutes) in the vehicle and 100 g MWCNT groups.  (D) TXB2 concentration in effluents 
collected during early reperfusion (first 15 minutes) in the vehicle and 100 g MWCNT groups.  
Data are mean ± SEM. *P < 0.05. 
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3.3.4. Left Ventricular Pressures 
Since left ventricular pressures can impact coronary flow, data on left ventricular pressure is 
provided for vehicle and 100 µg MWCNT in Figure 3.3.  No differences were observed in the 
maximum left ventricular (Max. LV) pressure in isolated hearts throughout reperfusion from rats 
instilled with vehicle or 100 µg MWCNT (Figure 3.3A).  The minimum LV (Min. LV) pressure 
was slightly elevated during the first 30 minutes of reperfusion in isolated hearts from the 100 µg 
MWCNT group compared to the vehicle group (Figure 3.3B). 
 
Figure 3.3 Left ventricular pressures 
Depression in coronary flow is not explained by large differences in left ventricular pressures.  
(A) Tracing of maximum left ventricular (Max. LV) pressure for vehicle and 100 g MWCNT.  
(B) Tracing of minimum left ventricular (Min. LV) pressure for vehicle and 100 g MWCNT.  
Data are mean ± SEM. *P < 0.05. 
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3.3.5. Cardiac ischemia/reperfusion injury 
The impacts of MWCNT exposure on ex vivo cardiac I/R injury in isolated hearts are presented 
in Figure 3.4.  Following I/R, infarct sizes were larger (P < 0.05) in isolated hearts from rats 
instilled with 100 µg MWCNT compared to hearts isolated from the vehicle group (Figure 
3.4A).  During reperfusion, the time until the first episode of ventricular tachycardia or 
fibrillation (VT/VF) was slightly decreased (not statistically different) in isolated hearts from rats 
instilled with 100 µg MWCNT as compared to vehicle (Figure 3.4B).  Additionally, cardiac 
arrhythmia scores generated for the 2 hr reperfusion period were similar (not shown), ranging 
from 4.2 ± 0.7 to 4.8 ± 0.4 in hearts isolated from vehicle instilled animals compared to those 
from the 100 µg MWCNT group, respectively.  We derived left ventricular developed pressure 
(LVDP) by subtracting the Min. LV pressure from the Max. LV pressure.  At the end of 
reperfusion protocols (Time = 140 minutes), ending LVDP was lower (P < 0.05) in hearts 
isolated from rats instilled with either 1 µg or 10 µg MWCNT as compared to hearts from rats 
instilled with vehicle (Fig. 3.4C).  However, the ending LVDP was not significantly lower in 
isolated hearts from the 100 µg MWCNT group compared to the vehicle group. 
 
Figure 3.4 Cardiac ischemia/reperfusion injury 
MWCNT exposure exacerbates cardiac I/R injury.  (A) Myocardial infarction following I/R 
shown as a percent of the zone at risk (ZAR).  (B) Time between the onset of reperfusion and the 
incidence of the first ventricular tachycardia or fibrillation (VT/VF).  (C) Mean LVDP values at 
the end of reperfusion protocols (time =140 minutes).  Data are mean ± SEM. *P < 0.05. 
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3.4. Discussion 
This study shows that pulmonary instillation of MWCNT 24 hrs prior to functional assessments 
in isolated hearts and cardiac I/R resulted in deleterious ex vivo cardiovascular endpoints.  These 
included increased myocardial infarction following I/R injury in isolated rat hearts, increased 
PVC prior to the ischemic bout, and depression of coronary flow during early reperfusion.  
MWCNT instillation also augmented ET-1 release from isolated hearts during early reperfusion 
and trends emerged suggesting that TXA2 release from the heart may be augmented prior to I/R 
and possibly during early reperfusion.  These findings are consistent with cardiovascular 
complications associated with particulate matter and air pollution exposure, which are dependent 
on decreasing size, increasing number per mass, and increasing surface area per mass of the 
particulate (16; 75; 98).  MWCNT have physicochemical properties similar to particulate matter, 
which has raised concerns about their ability to initiate cardiovascular complications following 
pulmonary exposure.However, until now it has not been clear whether pulmonary exposure to 
MWCNT would generate biological responses capable of altering intrinsic physiological 
processes of the heart. 
 
The MWCNT utilized in this investigation were physically characterized in a previous study 
showing that pulmonary exposure generated moderate pulmonary immune cell infiltration, 
collagen deposition, granuloma formation, and impairment of pulmonary function (173).  We 
used three bolus mass concentrations of MWCNT delivered by intratracheal instillation in rats 
for the intention of establishing whether MWCNT could exert effects beyond the lung, similar to 
what is known regarding ambient particular matter.  While this approach does not mimic real-
world exposure conditions or deposition patterns in the lung that would occur via inhalation, it 
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provides a model to test whether these MWCNT may influence the cardiovascular system.  
Future work should focus on similar endpoints following an inhalation exposure, which is more 
physiologically relevant and would provide critical data needed to develop a risk assessment 
paradigm. 
 
We used the isolated Langendorff rat heart model of I/R injury to examine cardiac endpoints that 
were dependent on changes in intrinsic characteristics of the heart and local signaling cascades, 
rather than MWCNT-induced changes in autonomic outflow and circulating humoral factors at 
the time of I/R.  The isolated heart model has been described elsewhere as an appropriate system 
for investigating the cardiovascular consequences of direct toxicology (147) or nanoparticle 
exposure, via delivery of nanoparticles within the isolated heart perfusate (152).  Our study 
demonstrates that the isolated heart model is also useful in assessing cardiovascular endpoints 
following pulmonary exposure to nanomaterials.  The model provided simultaneous 
measurements of electrical activity/arrhythmogenesis, cardiac function/contractility, and 
coronary flow throughout the I/R protocol (9).  We were able to compare these types of data to 
subsequent myocardial infarction and loss of LVDP that occurred by the end of I/R. 
 
The first novel finding in this study is that pulmonary exposure to MWCNT resulted in cardiac 
arrhythmogenic injury.  Hearts isolated from animals exposed to 10 or 100 μg of MWCNT had 
more PVC prior to the ischemic bout than those hearts taken from animals instilled with vehicle 
or 1 μg MWCNT.  These data are consistent with other studies that have noted increased 
arrhythmogenesis and PVC following pulmonary exposure to particulate matter (69; 80; 83).  
Contributing factors like MWCNT-dependent effects on autonomic outflow and/or circulating 
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humeral factors are greatly diminished in the isolated heart model, but neurotransmitter release 
from the remaining nerve endings in the heart could remain influential (152). 
 
One possible explanation for increased PVC at baseline is a possible increase in circulating 
oxidants in the hours following MWCNT exposure,which could prime the arrhythmogenic 
responses seen during the baseline ECG tracings.  There is supporting evidence that MWCNT 
have been shown to increase oxidative burdens in the vascular compartment (137) and increased 
PVC associated with particulate matter exposure have been linked to oxidative stress (83).  
Furthermore, it is possible that the basal PVC generation in isolated hearts could be a product of 
oxidant stress in myocardial tissue following pulmonary exposure to MWCNT.  Within the 
myocardium, oxidative stress is known to increase the propensity for arrhythmia (18), increase 
spontaneous calcium release from the sarcoplasmic reticulum (8), and introduce heterogeneity 
into myocardial action potentials (18), all of which are known to increase the proclivity for 
electrical dysfunction. 
 
Interestingly, during reperfusion, arrhythmia scores were only slightly higher in hearts from 
MWCNT exposed rats compared to those from the vehicle group, but trends for decreased time 
until the first VT/VF and increased time spent in VT/VF remained evident.  The 20 minute 
global ischemia challenge and subsequent reperfusion period likely pushed all the hearts in this 
study into such a highly arrhythmogenic state that MWCNT exposure was unable to worsen 
arrhythmogenesis during reperfusion. It is also tempting to speculate that the exacerbated size of 
myocardial infarction in isolated hearts taken from rats instilled with 100 µg MWCNT may have 
prevented worsening of the arrhythmogenic state of these hearts during reperfusion.  It has been 
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demonstrated that exacerbated myocardial infarction potentially insulatestissue against injury 
currents, which are abnormal electrical wave front propagations (102), and could also explain the 
similarity in arrhythmia scores during reperfusion between isolated hearts from rats instilled with 
vehicle or 100 μg MWCNT.  Clearly, further research will be needed in order to substantiate 
such a claim, but given the complexity and multifaceted aspects of cardiac I/R injury, such 
research would have multidisciplinary benefits outside of MWCNT-associated cardiotoxicity.  In 
either case, we propose that increased arrhythmogenesis at baseline following pulmonary 
exposure to MWCNT could possibly serve as an indicator of cardiac vulnerability to I/R, and 
further investigation of this observation should be warranted. 
 
The second novel finding in this study is the exacerbation of myocardial infarction following I/R 
in isolated rat hearts.  Given that increased levels of endogenous ET-1 has been linked to 
increasing myocardial infarction following I/R (127), it is possible that the increased ET-1 in the 
effluents of isolated hearts seen during reperfusion in the 100 μg MWCNT group contributed to 
the infarct expansion. MWCNT instillation also appeared to have some effect on post-I/R cardiac 
contractility.  In particular, those hearts isolated from rats instilled with lower mass concentration 
(1 or 10 μg) of MWCNT had lower LVDP by the end of reperfusion than those hearts isolated 
from the vehicle instilled rats.  LVDP is the difference between Min. LV pressure and Max. LV 
pressure and describes the force generating capacity of the left ventricle, and is thus commonly 
used as a measure of cardiac function.  Such a reduction in LVDP following I/R could result 
from cardiac stunning, arrhythmia, infarction, or any combination thereof (18; 184).  
Interestingly, hearts isolated from rats instilled with 100 μg of MWCNT did not demonstrate the 
same magnitude of LVDP reduction by the end of reperfusion that was seen following 1 g or 10 
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g MWCNT instillations.  TXA2 is linked to cardiac I/R and increased arrhythmias (34), and 
TXA2 has been shown to elevate intracellular Ca
2+
 in cardiac myocytes (41).  Considering that 
our study shows 100 g MWCNT instillation resulted in slight increases (P = 0.06) in TXB2 
concentrations measured in coronary effluents collected at baseline and early reperfusion, 
perhaps TXA2 briefly localized in high concentrations within zones of the myocardium 
enhanced myocyte contractility enough to preserve ventricular function in the face of expanding 
injury. 
 
The third novel finding in this study was that coronary reperfusion flow was depressed in hearts 
from rats instilled with 100 µg MWCNT when compared to the vehicle group.  Adequate 
coronary reflow is important due to the necessity of oxygen and nutrient delivery to the ischemic 
region in order to maintain cardiac contractility and myocardial viability, but these benefits are 
contrasted by increased oxygen free radical production in response to coronary reperfusion (24).  
Enhanced coronary vasoconstriction, and thus increased vascular resistance, is a central 
mechanism responsible for decreases in coronary blood flow, ultimately contributing to cardiac 
arrhythmogenesis and infarction during early post-ischemic reperfusion (99).  In this study, the 
modified Langendorff heart model delivers perfusate under constant pressure.  Therefore, the 
physical relationship of ΔR = P/ΔQ· were considered, where ΔR stands for the change in 
vascular resistance in the face of constant perfusion pressure (P) and an inverse change in the 
rate of perfusate flow (ΔQ·).  The depression in flow during early post-ischemic reperfusion of 
isolated hearts taken from rats previously instilled with 100 μg MWCNT suggested that vascular 
resistance was elevated.  We documented that Min. LV pressure was slightly increased in early 
reperfusion, which impart resistance to flow during cardiac diastole.  
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However, increased vascular resistance is more likely explained by the significant increase in 
concentration ET-1 that was measured in coronary effluents from the 100 g MWCNT 
group,especially considering the possibility of a concomitant elevation in the concentration of 
the vasoconstrictor TXA2.  ET-1 itself is a potent vasoconstrictor (25) and increased ET-1 levels 
in coronary effluents during reperfusion in hearts from the 100 µg MWCNT group are also 
consistent with the increased release of endothelins previously documented following particulate 
matter exposure and myocardial infarction (80). Cardiac responses to arrhythmogenic 
autocrine/paracrine agents like ET-1 could explain the increases in PVCat baseline (47; 80), 
though our data shows that ET-1 levels in preischemic coronary effluent samples from both the 
vehicle and 100 g MWCNT group were below detectible limits.  This brings into question the 
possibility that MWCNT exposure may perhaps modulate the specific local responses to ET-1 in 
cardiac myocytes and nodal tissue. 
 
Cardiac infarct size has also been shown to relate to the amount of ET-1 released (127), 
indicating that elevated ET-1 levels during reperfusion in isolated hearts from rats exposed to 
100 µg MWCNT may have also contributed to exacerbated myocardial infarction.  The role of 
ET-1 during myocardial I/R has been extensively reviewed (131), but the impact of MWCNT 
exposure on cardiac and coronary responses to ET-1 have not been previously identified.  Based 
on this study, a more in-depth assessment of myocardial and coronary artery responses to ET-1 
represents a logical focus point for future research following MWCNT exposure. 
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3.5. Chapter 3 conclusion 
Chapter 3 demonstrates that pulmonary exposure to MWCNT can have systemic impacts beyond 
the lung, and alters intrinsic properties of the heart capable of promoting cardiac I/R injury.  One 
key functional change induced by MWCNT outside of cardiac I/R injury, is baseline non-
autonomic cardiac arrhythmogenesis.  In terms of changes functional endpoints associated with 
cardiac I/R, increased release of ET-1, and possibly TXA2, may promote depression of coronary 
flow during reperfusion.  Each of these functional endpoints can provide an explanation for and 
contribute to post-I/R myocardial infarct expansion.  These findings indicate that acute 
pulmonary exposure to MWCNT, and possibly other ENP, has the potential to promote 
cardiovascular derangements similar to pulmonary exposure to particulate matter in air pollution.
CHAPTER 4 
INCREASED ISOMETRIC STRESS IN RESPONSE TO ENDOTHELIN-1 IN ISOLATED 
CORONARY ARTERIES 24 HOURS AFTER INTRATRACHEAL INSTILLATION OF 
MULTI-WALLED CARBON NANOTUBES 
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4.1 Introduction 
The increased use of MWCNT has raised concerns about human exposure.  Based on their size, 
it is possible that pulmonary exposure to MWCNT may generate physiological changes in the 
cardiovascular system similar to that of NP in air pollution.  MWCNT have been shown to 
translocate from the lung (139; 153).  Arterial responsiveness following inhalation of NP have 
been shown to be augmented COX-dependent mechanisms (88).  Pulmonary exposure to NP in 
vivo have been shown to disrupt vascular response profiles in isolate coronary arteries 24 hours 
after exposure (95; 111), including MWCNT (153).   Altered ETBR function has been linked to 
enhanced ET-1-mediated vasoconstriction following exposure to diesel components (30).  The 
COX pathway has been shown to promote exaggerated vasoconstriction in response to ET-1 
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during inflammation in other vascular beds, linked to increasing arachidonic acid metabolism 
through activation of the COX pathway, resulting in release of TXA2, and thus exaggerated 
vasoconstriction (81; 178).  Other evidence suggests that local coronary artery inflammation 
results in the induction of COX-2 and enhanced coronary vasoconstriction (136).  Induction of 
COX-2 has been linked to MWCNT exposure in macrophages (96), but COX-2 deficiency has 
been shown to exacerbate airway remodeling disorders in response to MWCNT exposure (140). 
 
In Chapter 3 we found that hearts isolated from rats 24 hours following a pulmonary exposure 
to100 g MWCNT demonstrated increased release of ET-1 during post-ischemic reperfusion 
with concomitant depression in coronary flow suggestive of increased coronary resistance.  
There were also slight elevations in TXB2 concentrations in isolated heart coronary effluents 
collected from the MWCNT group at baseline and early reperfusion.  Further, enhanced TXA2 
production likely reflects a role of COX in the cardiovascular detriments associated with 
pulmonary exposure to MWCNT.  These findings suggest that ET-1, COX and TXA2 may play 
a role in coronary tone following MWCNT exposure. 
 
Since coronary artery responses to ET-1 and TXA2 have not been studied following pulmonary 
exposure to MWCNT, it was thus the purpose of this study.  Here we used wire myography 
investigate coronary artery responses to ET-1 and TXA2 and the potential contribution of the 
COX pathway to enhance coronary artery stress (mN/mm
2
) generation following pulmonary 
exposure to 100 g MWCNT.  Specifically, we tested the hypothesis that intratracheal 
instillation of 100 g of MWCNT would enhance coronary smooth muscle stress generating 
capacity associated with ET-1, ETBR, COX, and TXA2.  Since ETBR as associated with the 
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vascular smooth muscle and endothelial layers of coronary arteries was also tested the 
endothelial-dependent component of this hypothesis by studying enhanced stress generation in 
intact and denuded coronary artery segments.  
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4.2 Materials and Methods 
4.2.1. Multi-walled carbon nanotubes and vehicle 
Vehicle instillate (10% surfactant/saline): Solution by volume is 90% sterile saline (0.9 % NaCl) 
and 10% pulmonary surfactant (Infasurf™, a gift from ONY, Inc., Amherst, NY).  Infasurf™ 
contains: (per mL of 0.9% NaCl solution) 35 mg total bovine phospholipids, of which 16 mg are 
disaturated phosphatidylcholine, and 0.7 mg bovine proteins, of which 0.44 mg are hydrophobic 
surfactant-associated protein C and 0.26 mg are hydrophobic surfactant-associated protein B 
(http://www.infasurf.com/about-infasurf/#composition). 
 
MWCNT instillate:  MWCNT were provided by NanoTechLabs, Inc. (Yadkinville, NC, USA).  
For 100 µg dosing suspensions, MWCNT were added to the vehicle instillate to a concentration 
of 0.5 mg/mL.  For 10 µg and 1 µg dosing solutions, 1:10 serial dilutions were performed with 
vehicle instillate.  Immediately prior to instillation MWCNT suspensions were sonicated in a 
cup-horn sonicator (Qsonica, LLC - Newton, CT, USA) for 2 minutes at 65% amplitude to reach 
and approximate energy output of 10,800 J. 
 
4.2.2. Animals 
Male Sprague-Dawley rats were purchased from Charles River (Morrisville, NC, USA).  Rats 
were 10-12 weeks of age at the time of purchase and housed in the Department of Comparative 
Medicine at East Carolina University.  Each rat had access to standard laboratory chow and 
water ad libitum in a temperature regulated facility (23 ± 1°C) under 12:12 hour light-dark 
cycles.  We provided each rat with a minimum of 5 days to acclimate prior to experimental 
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manipulations.  All use of rats in this study complied with protocols approved by the East 
Carolina University Institutional Animal Care and Use Committee. 
 
4.2.3. Instillations 
MWCNT were administered by intratracheal instillation.  Rats were placed under Isoflurane 
anesthesia and a 200 µL bolus of MWCNT or vehicle was placed at the opening of the trachea 
until aspirated, 24 hours prior to cardiopulmonary assessments.  After instillation, each rat was 
monitored for until normal grooming habits resumed. 
 
4.2.4. Bronchoalveolar lavage 
Rats were anesthetized deeply with Isoflurane and a pneumothorax was induced.  The heart was 
excised for coronary artery dissection and thoracic cage was removed for optimal visualization 
of the lungs, lower trachea and main bronchi.  Connective tissue surrounding the lung was 
resected and the left main bronchus was ligated.  A tracheotomy was performed allowing an 18 
gauge angiocatheter to be inserted and secured with 2-0 suture.  One bolus of Hanks balanced 
saline solution (23.1 mL/kg) was lavaged into the right lung three times successively.  Recovered 
bronchoalveolar lavage (BAL) fluid was centrifuged at 1000 x g for 10 minutes at 4°C.  The 
BAL supernatant was used for protein quantification. 
 
4.2.5. Differential cell counts 
The cell pellets were resuspended in 1 mL of fresh Hanks balanced saline solution and total cell 
counts were determined with a Cellometer® Auto X4 (Nexcelom Biosciences, LLC., Lawrence, 
MA, USA).  BAL fluid volumes containing 20,000 cells were centrifuged onto glass slides using 
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a Cytospin IV (Shandon Scientific Ltd., Cheshire, UK) and stained via a three step hematology 
stain (Richard Allan Scientific, Kalamazoo, MI, USA).  Cell differential counts were determined 
microscopically based on hematologic stain and cellular morphology.  A total of 300 cells per 
slide were counted to estimate cell percentage. 
 
4.2.6. Protein quantification 
BAL fluid protein quantification was performed using a standard Bradford protein assay.  In 
short, BAL fluid proteins were quantified using 5 µL of sample diluted 250 µL of Bradford 
reagent in duplicate wells of using a 96 well plate.  Absorbance values were read at 562 nm 
using a BIO-TEK
®
 Synergy HT plate reader (Winooski, VT, USA) and data were analyzed with 
Gen5 software (BIO-TEK
®
).  Absorbance values for each sample were compared to a standard 
curve generated using 2.0 - 0.0625 mg/mL bovine serum albumin. 
 
4.2.7. Isolated coronary wire myography 
After excision hearts were placed in ice cold physiological saline solution (PSS) containing 
(mM) 140 NaCl, 5.0 KCl, 1.6 CaCl2, 1.2 MgSO4, 1.2 3-[N-morpholino]-propane sulfonic acid 
(MOPS), 5.6 d-glucose, and 0.02 EDTA with a pH of 7.4 when heated to 37°C.  Segments of the 
LAD were carefully isolated and mounted into the chambers of a multi-channel wire myograph 
system (DMT 610M, Ann Arbor, MI).  Before being mounted into myographs, LAD segments 
selected for denuding were carefully passed on to a strand of human hair and the LAD lumen 
was gently rolled and rubbed along the hair to strip away the endothelium.  Following a 1 hour 
equilibration in oxygenated PSS, heated to 37°C with periodic washes, LAD segments were 
stretched progressively and length-tension relationships were established.  The law of Laplace 
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was used to determine the optimum resting tension for each vessel segment (90% of the internal 
circumference established at tensions equivalent to 100 mmHg), as described by Halpern and 
Mulvany (67).  After another 30 minute equilibration period, tissue viability was assessed by a 
10 minute K
+
 depolarization using 109 mM K
+
PSS, which is PSS containing equal molar 
substitution of Na
+
 with K
+
.  After washing out with fresh PSS and return to baseline tension, 1.0 
µM serotonin was delivered to precontract the LAD segments, followed by 3.0 µM ACh (5 
minutes each) to test for endothelial-dependent relaxation. 
 
4.2.8. Pharmacological agents for vascular studies 
Serotonin and ACh(Sigma-Aldrich,St. Louis, MO, USA) used during “wake-up” protocols and 
were dissolved in PSS.ET-1 (American Peptide Company, Inc., Sunnydale, CA) was dissolved in 
0.1% acetic acid.  FR139317 (R&D Systems, Inc., Minneapolis, MN) was dissolved in 100 mM 
DMSO.  Indomethacin (Sigma-Aldrich) was dissolved in 100% ethanol.  DUP-697 (R&D 
Systems, Inc.) was dissolved in 100 mM DMSO.  Ozagrel HCl (R&D Systems, Inc.) was 
dissolved in PSS.  AA2414 (R&D Systems, Inc.) was dissolved in 100 mM DMSO.  U46619 
(R&D Systems, Inc.) was dissolved in 100% ethanol.  HA-1077 (R&D Systems, Inc.) was 
dissolved in PSS.   
 
4.2.9. Coronary artery assessment of endothelin-1 responses 
After PSS washouts and tension relaxation, LAD segments were subjected to cumulative 
concentration-responses to ET-1 (0.1 nM - 1.0 µM).  Due to the robust nature of ET-1 responses, 
we conducted pair-wise measurements of ET-1 responses in separate LAD segments from the 
same heart, with and without pharmacological antagonist and an inhibitor for ET-1 receptors, 
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COX-1, COX-2, TXSorTP.  We used concentrations of the selective ETAR antagonist 
FR139317 that were selective for ETAR (10 nM) or a higher concentration that would also 
partially antagonize ETBR (10 μM), based on IC50 values reported by the supplier.  
Indomethacin (10 µM) was used as a general COX inhibitor and 1 µM DUP-697 was used to 
selectively inhibit COX-2. The TXS inhibitor Ozagrel HCl was used at 10 µM and the TP 
antagonist AA2414 was used at a 1.0 μM concentration.  The concentrations for Indomethacin, 
DUP-697, and AA2414 were selected just above the IC50 values reported by the supplier.  The 
Ozagrel concentration was titrated to response in the MWCNT group and then recapitulated in 
the vehicle group. 
 
4.2.10. Coronary artery assessments of thromboxane mimetic U46619 
Another group of LAD segments was used to develop a concentration-response curve for 
U46619, a TXA2 mimetic over the concentration range of 1.0 nM - 10 μM. 
 
4.2.11. Statistics 
All data are expressed as mean ± SEM and significant P-values (< 0.05) are marked or reported.  
Graphpad Prism software (version 5, LaJolla, CA, USA) was used to graph and analyze all data. 
BAL data were analyzed by t-test.  Isolated coronary artery vascular response curves were 
compared using Repeated Measures ANOVA with Bonferroni’s post-tests and non-linear 
regression analysis of the 4 parameter best-fit values (103).  Reported EC50 and Hillslope values 
were derived from normalized fits of each individual LAD concentration-response curve (0-
100% of response) and were compared by t-test. 
  
71 
 
4.3 Results 
4.3.1 Pulmonary responses to instillation 
We conducted BAL studies in order to estimate the extent of lung response following exposure 
to 100 µg MWCNT, and since Infasurf™ contains non-rat related proteins, we sought to confirm 
that no adverse pulmonary reactions occurred in response to the exogenous surfactant in vehicle 
instilled rats. These data are reported in Table 4.1.  Total protein concentrations in BAL fluid 
collected from rats exposed MWCNT were elevated (P < 0.05) compared to those from rats 
instilled with vehicle.  While total cell counts, macrophages and neutrophils were slightly in the 
MWCNT group compared to the vehicle group, the number of eosinophils was significantly 
elevated. 
 
Table 4.1 Bronchoalveolar lavage from multi-walled carbon nanotube studies 
 
Total Bronchoalveolar Lavage Fluid (BALF) Protein and Cellularity 
BAL samples collected 24 hrs following exposure in males, data expressed as mean ± SEM 
Protein 
(µg/mL) 
Cell Number 
(x 10
5
) 
Macrophages 
(x 10
5
) 
Neutrophils 
(x 10
3
) 
Eosinophils 
(x 10
3
) 
Epithelial 
Cells 
(x 10
3
) 
Vehicle 207 ± 13 3.8 ± 1.2 2.7 ± 0.8 35 ± 12 0.8 ± 0.4 22.7 ± 8.9 
MWCNT 272 ± 18* 4.6 ± 1.4 3.4 ± 1.1 42 ± 14 7.6 ± 2.4* 28.2 ± 8.5 
n 7-8 7 7 7 7 7 
* P < 0.05 vs. vehicle 
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4.3.2. Intact coronary artery responses to endothelin-1 and thromboxane mimetic 
Data for coronary artery stress production in response to ET-1 and the TXA2 mimetic U46619 
are presented in Figure 4.1 and Tables 4.2 (EC50 values) and 4.3 (Hillslope values).  Coronary 
artery stress (mN/mm
2
) responses to ET-1 in the MWCNT group yielded significant increases in 
stress production and altered curve progression compared to isolated LAD responses from the 
vehicle group (Figure 4.1A). Conversely, smooth muscle stress production in response to 
U46619 appeared diminished in LAD isolated from MWCNT instilled rats compared to vehicle 
but the curve progressions were significantly different between the MWCNT and vehicle groups 
(Figure 4.1B).  EC50 and Hillslope values for ET-1 and U46619 were all slightly shifted toward a 
more sensitized state in the MWCNT group compared to the vehicle group. 
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Figure 4.1 Intact coronary artery response to endothelin-1 and thromboxane mimetic 
MWCNT exposure enhances smooth muscle contraction in response to ET-1 in isolated coronary 
artery segments.  (A) Stress response curves for ET-1 in intact coronary artery segments isolated 
from MWCNT and vehicle instilled rats.  (B) Stress response curves for U46619 in intact 
coronary artery segments isolated from MWCNT and vehicle instilled rats.  Data are mean ± 
SEM.  *P < 0.05 vs. Vehicle by Repeated Measures ANOVA.  P < 0.05 vs. Vehicle indicated for 
non-linear regression analysis. 
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4.3.3. Denuded coronary artery responses to endothelin-1 
Data for denuded LAD responses to ET-1 are presented in Figure 4.2, and Tables 4.2 (EC50 
values) and 4.3 (Hillslope values).  Experiments involving denution of coronary arteries had low 
success rates just above 50% (7/12 survived the denuding process).  Intact vessels were only 
included if the corresponding denuding segment survived.  In those segments denuded coronary 
arteries isolated from rats instilled with MWCNT caused slight reductions in ET-1 stress 
generation compared to paired intact artery segments, enough so that the denuded MWCNT 
response curve looked more like the curve from intact LAD isolated from rats instilled with 
vehicle (Figure 4.2A).  However, denuding coronary artery segments also caused a slight 
diminishment in ET-1 stress response in the vehicle group compared to paired intact vessel 
segments from the vehicle group (Figure 4.2B). 
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Figure 4.2 Denuded coronary artery responses to endothelin-1 
(A) Stress response curves for ET-1 in denuded coronary artery segments isolated from 
MWCNT instilled rats.  (B) Stress response curves for ET-1 in denuded coronary artery 
segments isolated from Vehicle instilled rats.  Data are mean ± SEM. 
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4.3.4. Endothelin receptor antagonist-sensitive responses in intact coronary arteries 
The contribution of ETAR in response to ET-1 following MWCNT exposure was tested in 
Figure 4.3.  We incubated intact LAD segments with 10 nM FR139317, an ETAR-selective 
antagonist.  We found that at lower concentrations of ET-1, stress levels were similar between 
intact LAD isolated from the hearts of MWCNT exposed rats and vehicle exposed rats. 
However, at higher ET-1 concentrations the stress generated by intact ETAR antagonized LAD 
from the MWCNT group increased to levels similar to those of intact LAD isolated from the 
hearts of MWCNT instilled rats not antagonized with FR139317 (Figure 4.3A).  We also 
incubated intact LAD with 10 M FR139317, which will also partially antagonize ETBR.  In 
these experiments, intact LAD isolated from the hearts of MWCNT instilled rats antagonized 
with10 µM FR139317 produced stress similar to that seen in intact LAD from the vehicle group 
at higher ET-1 concentrations (10 nM – 1.0 µM) (Figure 4.3B).  EC50 and Hillslope values for 
ET-1 responses after incubation with 10 nM or 10 M FR139317 are reported in Tables 4.2 and 
4.3 respectively. 
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Figure 4.3 Endothelin receptor antagonist-sensitive responses in intact coronary 
arteries 
(A) ET-1 stress response curves from isolated LAD incubated with or without 10 nM FR139317, 
an endothelin A receptor (ETAR)-selective antagonist.  (B) ET-1 stress response curves from 
LAD isolated from rats instilled with 100 g MWCNT after being incubated with or without 10 
µM FR139317, which antagonizes ETAR and partially antagonizes endothelin B receptors 
(ETBR).  Data are mean ± SEM. 
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4.3.5. Coronary artery endothelin-1 responses and cyclooxygenase 
Data from isolated LAD responses to ET-1 with and without pharmacological manipulation of 
the COX-1 and COX-2 are shown in Figure 4.4.  Inhibition of LAD segments with 10 M 
Indomethacin, a general COX inhibitor, produced a 24% reduction in ET-1 stress in the 
MWCNT group to a level similar to the ET-1 stress responses of uninhibited LAD segments 
from vehicle instilled rats (Figure 4.4A).  The vehicle group showed little differences between 
ET-1-mediated stress responses in LAD inhibited with Indomethacin and those not inhibited. 
Inhibition of LAD segments with 1 µM DUP-697, a COX-2 selective inhibitor, produced a 15% 
reduction in ET-1 stress in segments isolated from rats previously instilled with MWNCT 
(Figure 4.4B).  The vehicle group also showed little differences between ET-1-mediated stress 
responses in LAD inhibited with DUP-697 and those not inhibited. 
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Figure 4.4 Cyclooxygenase inhibition in intact coronary arteries 
MWCNT exposure induces ET-1 responses in intact coronary arteries that are sensitive to 
pharmacological manipulation of the cyclooxygenase (COX) pathway.  (A) ET-1 stress-response 
curves from isolated LAD incubated with or without 10 µM Indomethacin, a general COX 
inhibitor, from rats instilled with 100 µg MWCNT.  (B) ET-1 stress-response curves from 
isolated LAD incubated with or without 1.0 µM DUP-697, a COX-2 selective inhibitor, from rats 
instilled with 100 µg MWCNT.Data are mean ± SEM. P < 0.05 by non-linear regression analysis 
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4.3.6. Coronary artery endothelin-1 responses and the thromboxane axis 
Data from isolated LAD responses to ET-1 with and without pharmacological manipulation of 
the TXS and TP are shown in Figure 4.5.  Inhibition of LAD segments with 10 M Ozagrel HCl, 
a TXS inhibitor, produced a 28% reduction in ET-1 stress in the MWCNT group to a level 
similar to the ET-1 stress responses of uninhibited LAD segments from vehicle instilled rats 
(Figure 4.5A).  The vehicle group showed little change in LAD stress responses to ET-1 after 
being inhibited Ozagrel HCl compared to the uninhibited ET-1 stress responses in LAD from the 
vehicle group.  When isolated LAD segments from MWCNT-instilled rats were incubated with 1 
µM AA2414 they showed a 27 % reduction in ET-1 stress generation compared to uninhibited 
LAD from the MWCNT group (Figure 4.5B).  LAD from the vehicle group also showed very 
little change in ET-1-mediated stress responses when inhibited withAA2414 compared to LAD 
from the vehicle group that were not inhibited. 
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Figure 4.5 Thromboxane axis blockade in intact coronary arteries 
MWCNT exposure induces ET-1 responses in intact coronary arteries that are sensitive to both 
pharmacological inhibition of TXA2 synthetase and pharmacological antagonism of TXA2 
receptor.  (A) ET-1 stress-response curves from isolated LAD incubated with or without 10 µM 
Ozagrel HCl, a TXA2 synthetase inhibitor.  (B) ET-1 stress-response curves from LAD 
incubated with or without 1.0 µM AA2414, a TXA2 receptor antagonist.  Data are mean ± SEM. 
P < 0.05 by non-linear regression analysis. 
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Table 4.2 Coronary arteryEC50s from multi-walled carbon nanotube studies 
 
EC50 Values [nm] (mean ± SEM, n) 
Vehicle MWCNT 
Figure 4.1:ET-1 (total) 14 ± 6.6, 14 4.7 ± 2.6, 12 
Figure 4.1:U46619 1930 ± 612, 7 1307 ± 394, 8 
Figure 4.2: ET-1 (intact) 16 ± 10, 4  14 ± 10, 3 
Figure 4.2: ET-1 (denuded) 12 ± 6.8, 4 17 ± 7.5, 3 
Figure 4.3 - 4.5:ET-1 1.7 ± 0.6, 8 1.5 ± 0.3, 8 
Figure 4.3:ET-1 + 10 nM FR 1.6 ± 0.9, 3 3.1 ± 1.5, 6 
Figure 4.3:ET-1 + 10 µM FR 2.0 ± 0.3, 4 1.6 ± 0.6, 5 
Figure 4.4:ET-1 + Indomethacin 2.4 ± 0.5, 8 1.6 ± 0.4, 8 
Figure 4.4:ET-1 + DUP697 1.7 ± 0.5, 4 2.5 ± 1.0, 8 
Figure 4.5:ET-1 + Ozagrel 1.5 ± 0.5, 3 3.7 ± 1.7, 4 
Figure 4.5: ET-1 + AA2414 1.5 ± 0.4, 7 1.4 ± 0.3, 8 
 
Table 4.3 Coronary artery Hillslopes from MWCNT studies 
 
Hillslope Values (mean ± SEM, n) 
Vehicle MWCNT 
Figure 4.1: ET-1 (total) 1.4 ± 0.1, 14 1.6 ± 0.1, 12 
Figure 4.1: U46619 1.3 ± 0.2, 7 1.5 ± 0.2, 8 
Figure 4.2: ET-1 (intact) 1.4 ± 0.1, 4 1.4 ± 0.2, 3 
Figure 4.2: ET-1 (denuded) 1.5 ± 0.1, 4 1.1 ± 0.1, 3 
Figure 4.3 - 4.5: ET-1 1.4 ± 0.1, 8 1.6 ± 0.2, 8 
Figure 4.3: ET-1 + 10 nM FR 1.9 ± 0.5, 3 1.3 ± 0.1, 6 
Figure 4.3: ET-1 + 10 µM FR 2.1 ± 0.9, 4 1.8 ± 0.1, 5 
Figure 4.4: ET-1 + Indomethacin 1.9 ± 0.5, 8 1.6 ± 0.2, 8 
Figure 4.4: ET-1 + DUP697 1.7 ± 0.2, 4 1.5 ± 0.2, 8 
Figure 4.5: ET-1 + Ozagrel 1.4 ± 0.1, 3 1.4 ± 0.1, 4 
Figure 4.5: ET-1 + AA2414 1.7 ± 0.2, 7 1.8 ± 0.3, 8 
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4.4. Discussion 
The major findings from this study are that pulmonary exposure to 100 g MWCNT resulted in 
significant enhancement ET-1-mediated stressproduction in coronary arteries isolated from rats 
24 hours after exposure.  Pharmacological approaches suggested that enhancement of ET-1-
mediated stress production is driven in large part by the COX/TXA2 axis.  TXS inhibitor 
Ozagrel and TP antagonist AA2414 both were capable of completely blocking the enhanced ET-
1 mediated coronary artery stress in LAD isolated from the rats instilled with 100 µg MWCNT.  
Examining the differences in the diminishment of ET-1-mediated stress production by the 
general COX inhibitor Indomethacin and the COX-2 selective inhibitor DUP-697, suggests that 
COX-2 may be more important in the response than COX-1.  These findings are consistent with 
other research showing that air pollution, particulate matter, and various ENP can yield arterial 
functional derangements (30; 31; 36; 88; 95; 111; 153; 176).  These findings support the 
concerns that pulmonary exposure to NP could promote cardiovascular derangements by specific 
physiological mechanisms, and that these physiological mechanisms may have an underlying 
vascular component. 
 
Since ET-1 has a significant role during cardiac I/R we tested the hypothesis that ET-1 
vasoconstriction in isolated LAD segments taken from rats exposed to 100 µg MWCNT would 
be enhanced in a COX/TXA2-dependent manner.  This hypothesis gained substantial support 
from the findings in Chapter 3 showing that pulmonary exposure to100 µg MWCNT promoted 
an increase in coronary effluent ET-1 concentrations and depression of coronary flow during 
early post-ischemic reperfusion.ET-1 is a potent vasoconstrictor released from endothelial cells, 
though not exclusively, to influence local vascular tone (25).  On vascular smooth muscle cells, 
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ET-1 acts on ETAR or ETBR, which are both coupled to Gq proteins.  On vascular endothelial 
cells, ET-1 can act on ETBR coupled to Gi proteins (40).  ETAR activation generally produces 
strong and prolonged vasoconstriction through Gq activation of phospholipase C, mobilization of 
inositol triphosphate and diacylglycerol from the lipid bilayer, which in turn activates Ca
2+
 
release from the sarcoplasmic reticulum and extracellular Ca
2+
 entry via voltage operated 
channels, producing vascular smooth muscle contraction (89).  ETBR activation on endothelial 
cells produces vasodilation by stimulating release of NO, which results in vascular smooth 
muscle relaxation (89). 
 
Research has suggested that tissue insult and inflammation can cause an augmented 
vasoconstriction in response to ET-1 dependent on ETBR activation (108; 132).  In our 
experiments, pharmacological inhibition of ETAR and partial inhibition of ETBR did not yield 
strong evidence that ETBR is solely responsible for the increase in ET-1-mediated stress 
production in coronary arteries following MWCNT exposure, but the claim is still plausible.  
Similarly, denudation of coronary artery segments did not provide strong support that the 
enhanced arterial response to ET-1 was entirely dependent upon vascular endothelial cells 
because denuded arteries from the vehicle group also showed a similar small reduction in stress 
response to ET-1.  These findings suggest that the experiments we preformed could be improved 
by increasing the N in denuded studies, and in conjunction with endothelium denudation also 
utilize ETAR and ETBR selective antagonist.  Such experiments could provide stronger evidence 
to support the hypothesis that MWCNT exposure results in endothelial cell/ETBR-dependent 
enhancement of coronary artery stress production in response to ET-1. 
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Under inflammatory conditions ET-1 has been linked to increasing arachidonic acid metabolism 
through activation of the COX pathway, resulting in release of TXA2 and thus exaggerated 
vasoconstriction (81; 178).  Our data suggest that COX and TXA2 play a role in coronary 
responses to ET-1, 24 hrs following MWCNT exposure. We also showed that LAD stress-
responses to U46619, a TXA2 mimetic, generated less stress in the MWCNT group compared to 
vehicle, possibly indicatingTPdesensitization in LAD isolated from rats exposed to 100 μg 
MWCNT.  Such an agonist-induced desensitization of TP is thought to occur through protein 
kinase C activation and TP phosphorylation by G-protein receptor kinases (55).  Therefore, if 
COX is basally active following MWCNT exposure, continued TXA2 release could result in 
coronary artery TP desensitization.  In either case, the involvement of the ET-1/COX/TXA2 
signaling axis may be a plausible mechanism to explain the depression of coronary flow during 
early reperfusion seen in the Langendorff isolated heart experiments in, following MWCNT 
exposure in Chapter 3. 
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4.5. Chapter 4 conclusion 
Chapter 4 demonstrates that pulmonary exposure to MWCNT in vivo can promote alterations in 
coronary artery smooth muscle function capable of enhancing coronary arterial tone.  Increased 
coronary tone, and thus increased coronary resistance, can impair perfusion to the myocardium.  
The heart is a metabolically active organ and specific adjustments in perfusion are both 
essentialand dependent upon precise responses of coronary arteries to local autocrine/paracrine 
agents.  If coronary arteries are over-responsive following pulmonary exposure to MWCNT as 
Chapter 4 suggests, then perfusion supply and demand mismatching could occur in the 
myocardium and result in cardiac injury.
CHAPTER 5 
PULMONARY EXPOSURE TO C60 PROMOTES EXPANSION OF CARDIAC I/R INJURY 
AND ENHANCES ET-1/COX MEDITATED STRESS PRODUCTION IN ISOLATED 
CORONARY ARTERY CONTRACTION 
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5.1. Introduction 
The heart may be susceptible to infarction in response to I/R injury following pulmonary 
exposure to multiple types of NP.  We have previously reported that post-I/R myocardial 
infarction worsens in a dose- and time-dependent manner following intratracheal (IT) instillation 
of MWCNT(165), cerium oxide nanoparticles (176) or ultrafine particulate matter (36).  
Cardiovascular detriments associated with ultrafine particulate matter may result from 
pulmonary inflammation, oxidative stress or direct particle effects following translocation (27; 
166).  Exposure to NP can result in systemic release of IL-6, IL-1β and tumor necrosis factor-α, 
as well as increased release of ET-1(39; 44; 66; 130).  Decreased release of nitric oxide and 
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hypercoagulability associated with exposure to ENP may contribute to impaired perfusion to 
zones of the myocardium, potentially increasing propensity for cardiac arrhythmia and 
myocardial infarction.  In Chapters 3, MWCNT were shown to increase PVC in isolated hearts 
and depress coronary flow during post-ischemic reperfusion, ET-1 release during reperfusion and 
expansion of post-I/R myocardial infarction (159).  Data collected in Chapter 4 data suggested 
that COX might contribute to enhanced coronary artery stress generation in response to ET-1 in 
LAD isolated from rats exposed to intratracheal MWCNT.  It is not clear whether these 
cardiovascular endpoints are unique to pulmonary routes of exposure or only occur in response 
to MWCNT.  In this chapter we will examine similar endpoints following exposure to a second 
carbon NP, C60. 
 
C60 is a spherical carbon allotrope first generated synthetically in 1985 but has likely been 
produced naturally in Earth’s environment for thousands of years, suggesting that human 
exposure to C60 is not necessarily a novel interaction (6).  Synthetic production of C60 on a 
commercial scale has increased the probability of human exposures occupationally and 
potentially even environmentally (90).  The growing number of industrial and medical 
applications for C60 are not surprising due to its unique physicochemical properties (115).  The 
medicinal uses for C60 spur from its capacity to function as an antiviral, photosensitizer, 
antioxidant, drug/gene delivery device and contrast agent in diagnostic imaging (7).  C60 have 
been found in occupational environments at concentrations of 23,856 – 53,119 particles/L air 
(79).  Given this potential for humans to encounter C60, assessments of in vitro cytotoxicity (22; 
78), in vivo biodistribution (90; 156), biopersistence (146) and adverse pulmonary responses to 
C60 have been conducted (6; 114; 126; 145).  Despite the effort put into developing a 
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toxicological profile for C60, the potential impacts of C60 on the cardiovascular system have 
rarely been examined. 
 
The purpose of this study was to examine cardiovascular detriments associated with different 
routes of exposure to C60 and to delineate the responses to C60 exposure in different genders.  
We examined the highest C60 concentration that we were able to achieve in solution (0.14 
g/L).  Here we delivered 28 g of C60 total, either by intratracheal or intravenous instillation 
in rats, a mass smaller than others that have been characterized for C60 exposure in rats (146). 
 
Based upon clinical findings associated with particulate matter exposure and our data with 
MWCNT, we hypothesized that I/R injury and pharmacological responses in isolated coronary 
arteries would depend upon the route of exposure and gender in rats instilled with C60. 
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5.2. Materials and Methods 
5.2.1. 60-carbon fullerenes 
C60 were formulated, characterized for zeta potential, and hydrodynamic sized by RTI 
International (Research Triangle Park, NC, USA).  Dry C60 was purchased from Sigma-Aldrich 
(St. Louis, MO, USA; Cat # 379646).  Due to its hydrophobicity, C60 was formulated with 
polyvinylpyrrolidone (PVP), and the dried pellets of C60/PVP were suspended in saline.  We 
dissolved PVP in saline to 1.4% for vehicle samples.  For more information about our 
formulation of C60 see the supplemental materials.  PVP coated C60 (C60) and PVP vehicles 
(vehicle) were analyzed for zeta potential and hydrodynamic diameter using a Malvern Zetasizer 
NanoZS (Malvern Instruments, Worcestershire, UK) with a 633nm laser source, 173° detection 
angle, and a clear disposable zeta cell.  The following protocol was used to characterize each 
suspension while at room temperature (25°C) and was designed to mimic the sample preparation 
for animal exposures.  Sterile normal saline (250 μL) was added to the vial containing the C60 or 
vehicle pellets and the vial was immediately placed in the cup horn sonicator and the sample was 
sonicated at 50% amplitude to obtain total energy output of 8880 J.  This process was repeated 
for two more vials.  The contents of the three vials were combined, vortexed for 10 sec and 
delivered into the Malvern cell for measurement using a syringe.  Size and zeta potential 
measurements were done using a Malvern disposable capillary cell (Malvern Instruments, 
#DTS1061C).  Measurements were performed in sequence of (i) 1st size determination; (ii) zeta 
potential measurement; (iii) 2nd size determination to confirm particle size after zeta potential 
measurement.  The sample cell remained undisturbed in the instrument throughout the three 
measurements, which took approximately 6-8 minutes each.  All experiments were performed in 
triplicate. 
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5.2.2. Particle number assessment 
C60 particle numbers were analyzed in solution by counting events in 10 µl of sample using a 
BD Accuri C6 flow cytometer (BD, San Jose CA, USA).  Briefly samples were prepared as 
described above.  Each sample was run through the flow cytometer to collect a total of 10 µl and 
analyzed for total events using BD Accuri C6 software with background events subtracted.  
Samples were analyzed on 3-4 separate runs with a cleaning cycle run between each sample 
measurement.  Each measurement was multiplied by 20 to obtain the particle number delivered 
to each rat (10 µL x 20 = 200 µL).  The mean of the triplicate measurement is reported. 
 
5.2.3. Animals 
Male and Female Sprague-Dawley rats were purchased from Charles River (Morrisville, NC, 
USA).  Rats were 10-12 weeks of age at the time of purchase and housed in the Department of 
Comparative Medicine at East Carolina University.  Each rat had access to standard laboratory 
chow and water ad libitum in a temperature regulated facility (23 ± 1°C) under 12:12 hour light-
dark cycles.  We provided each rat with a minimum of 5 days to acclimate prior to experimental 
manipulations.  All use of rats in this study complied with protocols approved by the East 
Carolina University Institutional Animal Care and Use Committee. 
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5.2.4. Instillations 
C60 were administered by intratracheal (IT) instillation of intravenous (IV) administration via 
the lateral tail vein.  A 200 µL bolus was delivered to each rat while under Isoflurane anesthesia, 
24 hours prior to cardiopulmonary assessments.  After instillation, each rat was monitored until 
normal grooming habits resumed. 
 
5.2.5. Bronchoalveolar lavage 
Only animals used for isolated coronary artery wire myography were used for BAL analysis.Rats 
were anesthetized deeply with Isoflurane and a pneumothorax was induced.  The heart was 
excised for coronary artery dissection and thoracic cage was removed for optimal visualization 
of the lungs, lower trachea and main bronchi.  Connective tissue surrounding the lung was 
resected and the left main bronchus was ligated.  A tracheotomy was performed allowing an 18 
gauge angiocatheter to be inserted and secured with 2-0 suture.  One bolus of Hanks balanced 
saline solution (23.1 mL/kg) was lavaged into the right lung three times successively.  Recovered 
BAL fluid was centrifuged at 1000 x g for 10 minutes at 4°C.  The BAL supernatant was used 
for protein quantification. 
 
5.2.6. Differential cell counts 
The cell pellets were resuspended in 1 mL of fresh Hanks balanced saline solution and total cell 
counts were determined with a Cellometer® Auto X4 (Nexcelom Biosciences, LLC., Lawrence, 
MA, USA).  BAL fluid volumes containing 20,000 cells were centrifuged onto glass slides using 
a Cytospin IV (Shandon Scientific Ltd., Cheshire, UK) and stained via a three step hematology 
stain (Richard Allan Scientific, Kalamazoo, MI, USA).  Cell differential counts were determined 
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microscopically based on hematologic stain and cellular morphology.  A total of 300 cells per 
slide were counted to estimate cell percentage. 
 
5.2.7. Protein quantification 
BAL fluid protein quantification was performed using a standard Bradford protein assay.  In 
short, BAL fluid proteins were quantified using 5 µL of sample diluted 250 µL of Bradford 
reagent in duplicate wells of using a 96 well plate.  Absorbance values were read at 562 nm 
using a BIO-TEK
®
 Synergy HT plate reader (Winooski, VT, USA) and data were analyzed with 
Gen5 software (BIO-TEK
®
).  Absorbance values for each sample were compared to a standard 
curve generated using 2.0 - 0.0625 mg/mL bovine serum albumin.  
 
5.2.8. Cardiac Ischemia/Reperfusion Injury in situ 
Cardiac I/R and myocardial infarct size analysis were performed by modifying the protocol we 
have previously reported using mice (165).  I/R experiments were conducted in a cohort of rats 
separate from those used for BAL, histology and coronary vascular studies.  Twenty-four hours 
following exposure to C60 or vehicle, male and female rats were anesthetized by an 
intraperitoneal injection of ketamine/xylazine (85/15 mg/kg, respectively) and given 
supplemental injections throughout the procedure to maintain anesthesia.  Body temperature was 
maintained at 37°C with a heating pad and TC-1000 Temperature Controller (CWE, Inc., 
Ardmore, PA, USA).  Rats were intubated via tracheostomy with a 16 gauge angiocatheter and 
mechanically ventilated at 81 breaths/minute with 100% O2 using a Harvard Inspira Advanced 
Safety Ventilator (Holliston, MA, USA).  Male rats were ventilated with 3.0 mL tidal volumes 
and female rats were ventilated with 2.8 mL tidal volumes.  A left parasternal thoracotomy was 
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performed and the pericardium was gently removed.  The LAD was identified and ligated ~4 mm 
distal to its origin between the conus arteriosus and the left atrium with 6-0 prolene suture tied 
over polyethylene tubing.  Effective occlusion of the LAD was confirmed visually by pallor 
distal to the ligature.  After 20 minutes of ischemia the tubing was removed and reperfusion was 
allowed for 2 hours.  One milliliter of blood was drawn from the inferior vena cava at the end of 
reperfusion for serum analysis. 
 
5.2.9. Determination of post-I/R myocardial infarct size 
Myocardial infarct size was determined by replacing the ligature at the original point of 
occlusion.  The aortic arch was cannulated and 1% Evans blue dye was perfused retrograde to 
delineate the myocardium subjected to I/R from the myocardium perfused throughout the 
procedure.  Hearts were excised and cut serially into 1 mm sections from the point of ligation to 
the apex.  Sections were incubated for 20 minutes in 0.1 - 1.0% triphenyltetrazolium chloride 
solution to demarcate infarcted from non-infarcted tissue.  Triphenyltetrazolium chloride is 
reduced enzymatically to a brick red color in viable tissue, while infarcted tissue remains pale.  
Both sides of all heart sections were digitally imaged.  Image J software was downloaded from 
the National Institutes of Health website (http://rsbweb.nih.gov/ij/) and used to determine the 
size of the left ventricle, zone at risk and the area of infarction. 
 
5.2.10. Post-ischemia/reperfusion cytokines 
Post-I/R serum cytokine concentrations were analyzed using serum samples collected 24 hours 
following exposure to C60 or vehicle.  Serum from male and female ratssubjected to I/R (Post-
I/R) were tested for concentrations of IL-6, MCP-1 and vascular endothelial growth factor 
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(VEGF) using a custom Milliplex MAP Cytokine/Chemokine Panel and Immunoassay (EMD 
Millipore, Billerica, MA, USA). The assays were run according to the manufacturer’s 
instructions.  Assays were analyzed using a Luminex 200 (Luminex, Austin, TX, USA) and 
results reported using Luminex xPONENT
®
 software version 3.1.  Any sample concentration 
that fell below the detection limit of the assay was reported as 0 pg/mL. 
 
5.2.11. Coronary artery isolation and vessel viability assessment 
Isolated coronary artery smooth muscle assessments were conducted 24 hours after IT or IV 
exposure to C60 or vehicle in male and female rats not subjected to I/R.  Rats were anesthetized 
deeply with Isoflurane and a pneumothorax was induced immediately.  One milliliter of blood 
was drawn directly from the right ventricle of the heart for serum analysis and then each animal 
was exsanguinated by cutting the inferior vena cava.  Coronary artery isolation was performed as 
we have previously described (159).  The heart was excised and placed in cold physiological 
saline solution (PSS); [mM] 140.0 NaCl, 5.0 KCl, 1.6 CaCl2, 1.2 MgSO4, 1.2 MOPS, 5.6 D-
glucose, and 0.02 EDTA (pH 7.4 @ 37°C).  Paired segments of the LAD, ~1 mm in length, were 
dissected away from the left ventricle between the circumflex artery and the first major 
bifurcation of the LAD.  Segments were mounted into chambers of a 610M multichannel wire 
myograph (DMT, Ann Arbor, MI, USA) using 0.04 mm diameter stainless steel wire.  After a 45 
minute equilibration period, length and lumen diameter were determined using the reticle 
micrometer of a stereo dissecting scope positioned over the chambers.  Resting tension was 
established by determining diameter-tension relationships and setting each segment to 90% of 
the lumen circumference achieved at 13.3 kPa (67).  An additional 45 minute equilibration 
period was allowed and then tissue viability was assessed by potassium depolarization for 7 
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minutes with 109 mM K
+
PSS (Equal molar substitution of K
+
 for Na
+
).  LAD segments were 
relaxed using successive washes with fresh PSS and endothelial integrity was tested by 
precontracting with 1.0 µM serotonin for 3 minutes followed by addition of 3.0 µM ACh.  Each 
LAD segment was washed with fresh PSS every 10 minutes for 30 minutes before starting 
experimental pharmacology protocols.  Myograph data was recorded in mN and was collected 
via computer using a PowerLab8/35 data acquisition interface (ADInstruments, Colorado 
Springs, CO, USA) and LabChart 7 Pro software (ADInstruments).  Data from each vessel 
segment were normalized to the vessel surface area (length x 2 x width) to yield segment stress 
(mN/mm
2
).  LAD segments that generated less than 2.0 mN/mm
2
 in response to K
+
PSS, 1.0 
mN/mm
2
 in response to 1.0 μM serotonin or relaxed less than 70% of the serotonin 
precontraction were not considered viable and excluded from further study. 
 
5.2.12. Pharmacology of the isolated coronary artery 
LAD were evaluated using cumulative concentration-response protocols designed to test 
endothelial-dependent vasorelaxation, modified from Tawfik et al. (158).  Paired LAD segments 
isolated from IT or IV exposed male and female rats were subjected to cumulative concentrations 
of serotonin (10 nM - 3.0 µM, 5-HT) and given 3 minutes to respond at each concentration 
before proceeding to the next concentration.  The coronary artery vascular smooth muscle stress 
(mN/mm
2
) generated in response to 5-HT of paired segments was averaged at each concentration 
for data reporting.  Upon verifying stable tension after addition of the highest concentration of 5-
HT, one of the paired segments was subjected to ACh (1.0 nM - 1.0 µM, ACh) to assess 
endothelial-dependent smooth muscle relaxation and the other segment was subjected to 
cumulative concentrations of the nitric oxide donor SNP (1.0 nM - 1.0 µM) to assess endothelial-
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independent smooth muscle relaxation.  Each LAD segment was given 3 minutes to respond at 
each concentration before proceeding to the next concentration. 
 
5.2.13. Isolated coronary artery endothelin-1 responses 
Coronary artery smooth muscle ET-1 responseswere conducted as we reported in Chapter 4.  
Following ACh and SNP protocols paired LAD segments from each group was subjected to ET-
1 concentration-response experiments.  These LAD segments were washed with fresh PSS every 
10 minutes for a minimum of 30 minutes before starting ET-1 protocols.  After confirming that 
basal resting tension had been reestablished, one of the paired LAD segments was incubated with 
10 µM of the non-selective COX inhibitor Indomethacin (Sigma-Aldrich, St. Louis, MO, USA) 
for 20 minutes.  Indomethacin remained in the preparation throughout the remaining protocol.  
ET-1was added cumulatively to each vessel chamber from 0.1 nM to 1.0 µM and given 7 
minutes to respond at each concentration before the next concentration was applied. 
 
5.2.14. Statistics 
All data are expressed as mean ± SEM unless otherwise reported with significant P-values (< 
0.05) marked.  Graphpad Prism software (version 5, LaJolla, CA, USA) was used to graph and 
analyze all data.  Cardiac I/R data were compared by ANOVA with Dunnett’s Multiple 
Comparison post-tests.  Isolated coronary artery vascular response curves were compared using 
Repeated Measures ANOVA with Bonferroni’s post-tests and non-linear regression analysis of 
the 4 parameter best-fit values (103).  Reported EC50 and Hillslope values were derived from 
normalized fits of each individual LAD concentration-response curve (0-100% of response) and 
were compared by t-test across treatment within delivery routes and by ANOVA against matched 
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treatments across delivery routes and naïve controls.  Statistical power and group size were based 
on power analysis of our cardiac I/R experiments in order to understand variability in 
physiological mechanisms that may contribute to any myocardial vulnerability to infarction 
following C60 exposure. 
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5.3 Results 
5.3.1. 60-carbon fullerene characterization  
The physical characteristics of both PVP vehicle and C60/PVP suspensions are outlined in Table 
5.1.  The hydrodynamic size characteristics varied only slightly over a 38 minute testing period 
despite the fact that a zeta potential in the range of 0-5 mV is indicative of rapid flocculation or 
coagulation.  The flowcytometery data indicated that there were approximately 25,791 ± 1351 
particles of C60/10 µL of sample.  This means that approximately 515,825 ± 27,014 C60 
particles were delivered to each rat in the IT and IV C60 groups.  If theC60/PVP particles are 
spherical, we can estimate that a particle surface area of 23.2 mm
2
 was administered to each rat.  
Based on calculations, the dispersion of the PVP samples should equal 21.6 µg/µL and for C60 
samples should equal 21.3 µg/µL. 
 
Table 5.1 60-carbon fullerene particle characterization 
Physical characterization ofC60 suspensions (mean ± SEM) 
Hydrodynamic size, nm 371 ± 0.6 
Zeta potential 1.6 mV 
Particle number (per per 10 µL) 25,791 ± 1351 
Calculated surface area (per 10 µL) 11.15 mm
2
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5.3.2. Bronchoalveolar lavage fluid analysis 
BAL protein and differential cell counts for male rats are reported in Table 5.2. BAL protein and 
differential cell counts for female rats are reported in Table 5.2.  Only two important differences 
were identified, including increased total protein concentrations (P < 0.05) in BAL fluid 
collected from male rats exposed to IV C60 compared to IT C60 exposed males, and increased 
number of eosinophils in BAL fluid collected from IT C60 females compared to IT vehicle 
females. 
 
Table 5.2 Bronchoalveolar lavage from 60-carbon fullerene studies male rats 
 
Total Bronchoalveolar Lavage Fluid (BALF) Protein and Cellularity 
BAL samples collected 24 hrs following exposure in males, data expressed as mean ± SEM 
Protein 
(µg/mL) 
Cell Number 
(x 10
5
) 
Macrophages 
(x 10
5
) 
Neutrophils 
(x 10
3
) 
Eosinophils 
(x 10
3
) 
Epithelial Cells 
(x 10
3
) 
IT IV IT IV IT IV IT IV IT IV IT IV 
Vehicle 
560 ± 
149 
638 ± 
100 
5.7 ± 
1.4 
3.5 ± 
0.9 
5.3 ± 
1.3 
5.7 ± 
0.7 
14.2 ± 
10 
2.1 ± 
0.3 
1.9 ± 
1.1 
2.4 ± 
2.4 
6.6 ± 
2.4 
1.7 ± 
1.7 
C60 
316 ± 
55 
750 ± 
138* 
3.9 ± 
0.8 
6.9 ± 
1.7 
4.0 ± 
0.7 
2.5 ± 
1.2 
13.3 ± 
12 
1.7 ± 
1.4 
0.5 ± 
0.5 
<1 
2.8 ± 
0.3 
8.2 ± 
2.6 
n 4-5 4-6 3-5 3-5 3-5 3-5 
* P < 0.05 vs. IT C60 
 
Table 5.3 Bronchoalveolar lavage from 60-carbon fullerene studies female rats 
 
Total Bronchoalveolar Lavage Fluid (BALF) Protein and Cellularity 
BAL samples collected 24 hrs following exposure in females, data expressed as mean ± SEM 
Protein 
(µg/mL) 
Cell Number 
(x 10
5
) 
Macrophages 
(x 10
5
) 
Neutrophils 
(x 10
3
) 
Eosinophils 
(x 10
3
) 
Epithelial Cells 
(x 10
3
) 
IT IV IT IV IT IV IT IV IT IV IT IV 
Vehicle 
252 ± 
28 
195 ± 
8.2 
7.8 ± 
1.9 
4.1 ± 
0.6† 
1.6 ± 
0.9 
3.3 ± 
0.4 
35.0 ± 
25.3 
<1 
0.25 ± 
0.25* 
1.7 ± 
1.7 
132 ± 
90 
346 ± 
132 
C60 
206 ± 
24 
226 ± 
41 
7.1 ± 
1.2 
3.5 ± 
0.5* 
0.9 ± 
0.3 
3.1 ± 
1.1 
27.5 ± 
11.1 
<1 
12.5 ± 
7.5 
3.6 ± 
0.6 
75.0 ± 
32.8 
362 ± 
59* 
n 5-6 4-6 4-6 4-6 4-6 4-6 
* P < 0.05 vs. IT C60, †P < 0.05 vs. IT vehicle 
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5.3.3. Cardiac ischemia/reperfusion injury 
The impact of IT or IV exposure to C60 on cardiac I/R injury in male and female rats is 
represented in Figure 5.1.  Following I/R we found expansion of myocardial infarction in male 
rats exposed to C60 suspensions when compared to the infarct size measured in the vehicle 
groups.  Male rats demonstrated no significant differences between the extent of I/R injury 
across IT or IV exposure routes.  Female rats also suffered myocardial infarct expansions 
following I/R in both C60 exposed groups compared to infarct sizes in hearts from vehicle 
groups.  Female rats did show significantly larger myocardial infarctions following IT exposure 
to C60 as compared to IV exposure to C60. 
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Figure 5.1 Cardiac ischemia/reperfusion injury with 60-carbon fullerene exposure  
Male and Female rats were subjected to regional cardiac I/R (20/120 minute) injury in situ, 24 
hrs following intratracheal (IT) or intravenous (IV) delivery of C60 or vehicle.  In either case 
C60 exposure exacerbated myocardial infarction.  Within each delivery route, infarct sizes in the 
male groups were larger than those in females.  Between delivery routes, the females had larger 
infarctions in response to IT C60 exposure compared to IV exposure. *P < 0.05 by two-way 
ANOVA, N = 4-5 
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5.3.4. Post-I/R serum cytokines 
The influence of IT or IV exposure to C60 on post-I/R concentrations of serum IL-6, MCP-1 and 
VEGF from male and female rats is presented in Figure 5.2.  IL-6 concentrations were greater in 
serum collected post-I/R from male rats exposed to IV C60 when compared to serum collected 
from male rats exposed to IV vehicle and male rats exposed to IT C60 (Figure 5.2A).  Female 
rats exposed to IV C60 had significantly lower serum IL-6 concentrations than IV C60 exposed 
males.  Serum IL-6 concentrations were unaltered between all IT groups and IV exposed 
females.  MCP-1 showed a similar profile to IL-6.  MCP-1 concentrations were greater in serum 
collected post-I/R from male rats exposed to C60 IV when compared to serum collected from 
male rats exposed to IV vehicle, male rats exposed to IT C60 and female rats exposed to C60 IV 
(Figure 5.2B).  Female rats exposed to IV C60 had significantly lower serum MCP-1 
concentrations than IV C60 exposed males.  Serum MCP-1 concentrations were unaltered 
between all IT groups and IV exposed females.  VEGF was variable and slightly elevated in 
females exposed to IT and IV C60, though not significantly different than any other group 
(Figure 5.2C). 
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Figure 5.2 Post-ischemia/reperfusion serum cytokine concentrations 
Serum samples were collected from male or female rats subjected to cardiac I/R injury, 24 hrs 
following intratracheal (IT) or intravenous (IV) delivery of C60 or vehicle.  (A) Interleukin-6 
(IL-6) concentrations were significantly higher in serum collected from male rats exposed to IV 
C60 compared to male IV vehicle, male IT C60, and female IV C60.  (B) Monocyte chemotactic 
protein-1 (MCP-1) concentrations were also increased in serum collected from male rats exposed 
to IV C60 compared to male IV vehicle, male IT C60, and female IV C60.  (C) Vascular 
endothelial growth factor (VEGF) concentrations were similar in serum collected from all 
groups.  *P <0.05 by two-way ANOVA, N = 3-4. 
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5.3.5. Male rat coronary artery pharmacology 
Pharmacological response curves generated in coronary artery (LAD) segments isolated from 
male rats 24 hrs after exposure to IT and IV administration of C60 or vehicle suspensions are 
shown in Figure 5.3.  The associated EC50values are reported in Table 5.4 and associated 
Hillslope values are reported in Table 5.5.  LAD isolated from male rats exposed to IT C60 
showed vascular smooth muscle stress (mN/mm
2
) generation curves for 5-HT trending toward (P 
= 0.06) a leftward shift (i.e. sensitization) compared to the vehicle group (Figure 5.3A).  Stress 
response curves for 5-HT were not altered in LAD isolated from male rats treated with IV C60 or 
vehicle (Figure 5.3B).  ACh vascular smooth muscle relaxation responses were not different 
between LAD isolated from male rats exposed to IT C60 and vehicle (Figure 5.3C).  The LAD 
from IV C60 exposed males yielded an ACh vascular smooth muscle relaxation response curve 
with significantly different best-fit values than the curve generated by LAD isolated from vehicle 
exposed males, despite the overall variability ACh sensitivity (Figure 5.3D).  As indicated in 
Table 3, IT vehicle and IT C60 ACh EC50s from male rats were significantly higher than those 
from naïve males.  The ACh response curve produced by LAD from IV vehicle exposed males 
was not different from ACh responses in LAD isolated from naïve controls (curves not shown).  
Vascular smooth muscle relaxation curves generated by LAD in response to SNP were not 
different between IT exposed males (Figure 5.3E) or IV exposed males (Figure 5.3F).  
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Figure 5.3 Coronary artery pharmacology in male rats 
Segments of the coronary artery (LAD) were isolated from male rats 24 hrs following 
intratracheal (IT) or intravenous (IV) delivery of C60 or vehicle.  (A) Cumulative concentration-
response curves for serotonin (5-HT) revealed a trend for sensitized vascular smooth muscle 
contraction in coronary arteries from IT C60 exposed rats, which were not seen following IV 
delivery of C60.  (B) Cumulative concentration-response curves for 5-HT in coronary artery 
smooth muscle of LAD segments isolated from IV exposed rats.  (C) Cumulative concentration-
response curves for acetylcholine (ACh) showed no changes following IT exposure.  (D) The IV 
C60 ACh curve was rightward shifted compared to the vehicle curve.  (E) Cumulative 
concentration-response curves for sodium nitroprusside (SNP) were similar between vehicle and 
C60 groups following IT exposure and IV exposure.  (F) Cumulative SNP concentration-
response curves from LAD isolated from IV exposed rats. †for P < 0.05 by regression analysis of 
best-fit curve values.  Reported P-values for ∆EC50 were determined by t-test, N = 4-5. 
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Table 5.4 Male rat coronary artery EC50s from 60-carbon fullerene studies 
 
Male Rat EC50s [nM] (mean ± SEM) 
Intratracheal (IT) Delivery Intravenous (IV) Delivery 
C60 Vehicle P-Value, n C60 Vehicle P-Value, n 
5-HT 559 ± 104 871 ± 130 0.06, 4 766 ± 113 675 ± 59 0.25, 4 
ACh 265 ± 45 239 ± 34 0.33, 4 231 ± 80 97 ± 69 0.14, 4 
SNP 116 ± 24 76 ± 18 0.13, 4 76 ± 21 104 ± 53 0.32, 4 
ET-1 38 ± 20 48 ± 15 0.49, 6 26 ± 18 113 ± 86 0.35, 5 
 
Table 5.5 Male rat coronary artery Hillslopes from 60-carbon fullerene studies 
 
Male Rat Hillslope Values (mean ± SEM) 
Intratracheal (IT) Delivery Intravenous (IV) Delivery 
C60 Vehicle P-Value, n C60 Vehicle P-Value, n 
5-HT 1.7 ± 0.1 3.2 ± 0.7 0.10, 4 2.0 ± 0.2 1.9 ± 0.1 0.57, 4 
ACh 2.6 ± 0.4 1.7 ± 0.1 0.10, 4 3.8 ± 0.8 1.8 ± 0.1 0.09, 3-4 
SNP 2.4 ± 0.6 2.2 ± 0.3 0.77, 4 2.1 ± 0.3 1.9 ± 0.1 0.50, 4 
ET-1 1.3 ± 0.2 1.0 ± 0.05 0.09, 6 1.1 ± 0.1 1.0 ± 0.2 0.67, 5 
 
 
5.3.6. Female rat coronary artery pharmacology 
Pharmacological response curves generated in coronary artery (LAD) segments isolated from 
female rats 24 hrs after exposure to IT and IV administration of C60 or vehicle suspensions are 
shown in Figure 5.4.  The associated EC50 are reported in Table 5.6 and Hillslope values are 
reported in Table 5.7.  Stress generation curves for 5-HT were not significantly different between 
LAD isolated from female rats exposed to IT C60or vehicle (Figure 5.4A).  LAD vascular 
smooth muscle stress generationin response to 5-HT wasnot different between LAD from the 
female IV C60 or IV vehicle groups (Figure 5.4B).  Vascular smooth muscle relaxation in 
response to ACh was not different between LAD isolated from female rats exposed to IT C60 
orIT vehicle (Figure 5.4C).  The vascular smooth muscle relaxation response curves for ACh 
appeared to show a desensitization in the LAD from IV C60 exposed femalesbut the responses 
were not statistically different from females exposed to IV vehicle (Figure 5.4D).  The best-fit 
values for the vascular smooth muscle relaxation curve for SNP in IT C60 exposed females were 
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significantly differentthan those from coronary arteries isolated from IT vehicle exposed females 
(Figure 5.4E).  SNP smooth muscle relaxation responses in isolated coronary artery segments 
isolated from IV C60 exposed females were only slightly leftward shifted compared to coronary 
artery segments from IV vehicle exposed females (Figure 5.4F). 
 
Figure 5.4 Coronary artery pharmacology in female rats 
Segments of the coronary artery (LAD) were isolated from female rats 24 hrs following 
intratracheal (IT) or intravenous (IV) delivery of C60 or vehicle.  (A) Cumulative concentration-
response curves for serotonin (5-HT) mediated vascular smooth muscle contraction in LAD from 
IT C60 exposed rats.  (B) Cumulative concentration-response curves for 5-HT in coronary artery 
smooth muscle of LAD segments isolated from IV exposed rats.  (C) Cumulative concentration-
response curves for acetylcholine (ACh) showed no changes following IT exposure.  (D) The IV 
C60 ACh curve a slight rightward shifted compared to the vehicle curve.  (E) Cumulative 
concentration-response curves for sodium nitroprusside (SNP) showed less smooth muscle 
relaxation in LAD isolated fromIT C60 compared to IT vehicle groups.  (F) Cumulative SNP 
concentration-response curves from LAD isolated from IV exposed rats showed slight leftward 
shifts in EC50 from LAD coronary artery smooth muscle relaxation responses from C60 exposed 
females compared to the IV vehicle curves. †for P < 0.05 by regression analysis of best-fit curve 
values.  Reported P-values for ∆EC50 were determined by t-test, N = 4-5. 
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Table 5.6 Female rat coronary artery EC50s from 60-carbon fullerene studies 
 
Female Rat EC50s [nM] (mean ± SEM) 
Intratracheal (IT) Delivery Intravenous (IV) Delivery 
C60 Vehicle P-Value, n C60 Vehicle P-Value, n 
5-HT 813 ± 128 1268 ± 497 0.40, 5 932 ± 156 990 ± 275 0.86, 5 
ACh 1419 ± 843 139 ± 28 0.16, 5 619 ± 233 1085 ± 558 0.46, 5 
SNP 19 ± 3 21 ± 4 0.64, 5 14 ± 4 24.1 ± 4.1 0.16, 5 
ET-1 29 ± 20 6.5 ± 2.4 0.31, 5 13 ± 7 23 ± 16 0.56, 5 
 
Table 5.7 Female rat coronary artery Hillslopes from 60-carbon fullerene studies 
 
Female Rat Hillslope Values (mean ± SEM) 
Intratracheal (IT) Delivery Intravenous (IV) Delivery 
C60 Vehicle P-Value, n C60 Vehicle P-Value, n 
5-HT 1.4 ± 0.4 1.0 ± 0.2 0.39, 5 1.3 ± 0.4 1.3 ± 0.2 0.95, 5 
ACh 1.0 ± 0.4 1.6 ± 0.3 0.29, 5 1.0 ± 0.2 1.7 ± 0.5 0.19, 5 
SNP 1.6 ± 0.3 2.1 ± 0.4 0.35, 4 2.0 ± 0.3 1.9 ± 0.3 0.79, 5 
ET-1 1.4 ± 0.3 1.1 ± 0.3 0.41, 5 1.1 ± 0.2 1.0 ± 0.2 0.67, 5 
 
 
5.3.7. Male and female coronary artery responses to endothelin-1 
Vascular smooth muscle contraction responses to ET-1 are shown in Figure 5.5 for LAD 
segments isolated from male and female rats exposed to IT or IV C60 and vehicle.  EC50 and 
Hillslope values for ET-1 concentration-response curves are also provided in Tables 5.4 and 5.5 
for LAD collected from male rats and Tables 5.6 and 5.7 for LAD collected from female rats.  
Male rats instilled with C60 IT demonstrated enhanced stress in response to ET-1 compared to 
vehicle (Figure 5.5A).  This response was not seen in male rats following IV C60 exposure 
(Figure 5.5B) or female rats instilled with C60 IT (Figure 5.5C) or C60 IV (Figure 5.5D). 
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Figure 5.5 Male and female coronary artery responses to endothelin-1 
Segments of the coronary artery were isolated from male and female rats 24 hrs following ITor 
IV delivery of C60 or vehicle.  (A) Cumulative concentration-response curves for ET-1 showed 
enhanced stress generation during isometric vascular smooth muscle contraction in LAD from IT 
C60 instilled male rats compared to vehicle.  (B) Cumulative concentration-response curves for 
ET-1 stress generation during isometric vascular smooth muscle contraction in LAD from IV 
C60 or vehicle instilled male rats.  (C) Cumulative concentration-response curves for ET-1 stress 
generation during isometric vascular smooth muscle contraction in LAD from IT C60 instilled 
female rats.   (D) Cumulative concentration-response curves for ET-1 stress generation during 
isometric vascular smooth muscle contraction in LAD from IV C60 instilled female rats.  †for P 
< 0.05 by regression analysis of best-fit curve values.  N = 5-6. 
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5.3.8. Indomethacin-sensitive coronary artery responses to endothelin-1.  The ability of 
Indomethacin, a general COX inhibitor, to influence ET-1 mediated isometric stress (mN/mm
2
) 
generation in LAD isolated from male rats exposed to IT C60is depicted in Figure 5.6.  LAD 
segments isolated from rats exposed to C60 generated more stress in response to ET-1 than LAD 
collected from vehicle exposed rats (Figure 5.6A).  Enhanced stress was lower in paired LAD 
isolated from C60 exposed rats that were incubated with 10 µM Indomethacin, a general COX 
inhibitor, for 20 minutes immediately prior to ET-1 protocols (Figure 5.6B).  LAD collected 
from vehicle instilled rats did not show sensitivity to Indomethacin inhibition of COX during 
ET-1 mediated vascular smooth muscle contractionbut Indomethacin inhibition was able to 
restore the C60 stress generation response to ET-1 to the level of the vehicle group (Figure 
5.6C). 
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Figure 5.6 Indomethacin-sensitive coronary artery responses to endothelin-1 
Segments of the coronary artery were isolated from male rats 24 hrs following IT delivery of 
C60 or vehicle.  Paired LAD segments isolated from each of the IT exposed male rats were also 
treated with 10 µM Indomethacin, a general COX inhibitor, 20 minutes prior to ET-1 
administration.  (A) Cumulative concentration-response curvesdeveloped in response to ET-1 
revealed enhanced isometric stress generation in coronary arteries from C60 exposed rats when 
compared to vehicle.  (B) Coronary segments isolated from C60 exposed rats showed sensitivity 
to Indomethacin during cumulative concentration-responses to ET-1 when compared to vehicle.  
(C) Data combined from vehicle and C60 groups during ET-1/Indomethacin experiments showed 
that LAD isolated from vehicle instilled rats were not sensitive to Indomethacin during 
cumulative concentration-responses to ET-1 and that Indomethacin restored LAD smooth muscle 
contractile response from IT C60 exposed rats to the level of those from the vehicle group.  †for 
P < 0.05 by regression analysis of best-fit curve values, * for P < 0.05 by Repeated Measures 
ANOVA on matching concentration data points, N = 6. 
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5.4. Discussion 
 This study demonstrated that IT C60 exposure of Sprague-Dawley rats resulted in deleterious 
cardiovascular consequences.  This included C60 induced expansion of myocardial infarction 
following cardiac I/R and enhancement of ET-1 mediated stress generation of isolated segments 
of the LAD, potentially indicative of increased coronary vascular resistance.  These results align 
with the paradigm that pulmonary exposure to nanosized particles has the potential to generate 
cardiovascular impairments (16; 105; 109; 144) and supports our previous report that enhanced 
coronary artery tone following IT exposure to engineered carbon nanomaterials may exacerbate 
cardiac I/R injury (159).  The present study goes further to demonstrate that IT exposure to C60 
may generate cardiovascular detriments via mechanisms unique from those produced by IV 
exposure to C60.  While expansion of post-I/R myocardial infarction resulted from both IT and 
IV exposure to C60, our study uncovered impairment of ACh mediated coronary artery 
relaxation, increased serum IL-6 and serum MCP-1 associated with IV C60 exposure and not IT 
C60 exposure in male rats.  This study also offers other evidence of potential importance in that 
female rats were more susceptible to I/R injury following IT C60 exposure than they were 
following IV C60 exposure, a trend that did not emerge in male rats.  Female rats also showed 
C60 exposure route sensitivity in coronary artery relaxation responses for SNP.  The diminished 
SNP response in the female IT C60 group was not seen in the female IV C60 group.  The female 
IT C60 group also had significant eosinophilia when compared to the IT vehicle female group.  
These findings provide a possible explanation for why infarct sizes were larger in the female IT 
C60 group than infarcts in the female IV C60 group.  These types of gender sensitivities to 
nanomaterials are not well understood and may be an important area for future research. 
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C60 fullerene is emerging as an advantageous engineered nanoparticle due to its highly 
modifiable structure, potentially providing it with countless applications in material science 
(110), optics, cosmetics (163), electronics, green energy (115) and medicine (50).  With C60 use 
increasing, the toxicological and regulatory communities have been investigating the potential 
adverse impacts associated with C60 exposure, bringing into question potential routes of 
exposure and use of comparable doses.  Pulmonary exposure is expected to occur in occupations 
requiring direct work with raw C60.  In occupational settings C60 have been detected at 
concentrations ranging from 23,856 - 53,119 particles/L air (79).  Considering that humans 
breathe between 360 - 600 L of air an hour, even a brief 1 hour occupational inhalation exposure 
could deposit 8,500,000 - 31,500,00 C60 particles into the lungs.  We delivered 515,825 ± 
27,014 C60 particles to each rat in the C60 groups from our study.  Given the size difference 
between rats and humans, the 28 g C60 burden we administered to each rat was relatively large, 
but comparable to potential human doses. 
 
Studies have shown that IT instillation of 100 µg C60 in rats resulted in a pulmonary burden 
half-life of about 15 days (146) and minimal pulmonary inflammation 3 days after exposure 
(126).  The medical applications of C60 suggest that IV exposure in humans is likely.  In a study 
where C60 was administered IV to male rats once per day for four days (approximately 929 µg 
C60 total), C60 accumulation in the lungs was prominent from 1 day post-exposure out to 28 
days post-exposure (90).  Another IV study on the biodistribution of radiolabeled C60 in 
pregnant and lactating rats showed moderate accumulation of C60 in the lungs (156). We 
delivered 28 µg of C60 per rat in this study (93.33 µg/kg based on a 300 g rat).  This exposure 
mass is comparable and often times lower than the doses of other C60 studies cited.  Though we 
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found an increase in eosinophils in the female IT C60 group compared to the female IT vehicle 
group, our study falls in line in line with many of those studies supporting the possibility that 
C60 delivered IT or IV may produce minimal pulmonary inflammation, if any. 
 
Despite the various investigations into pulmonary and in vitro responses to C60, examinations of 
cardiovascular impacts are scarce.  The model of in situ cardiac I/R injury used in this study has 
been well established in our laboratory as a toxicological endpoint following pulmonary 
exposure to various types of ultrafine and nanosized particles (36; 82; 165).  Here we tested the 
hypothesis that pulmonary exposure to C60 would result in expansion of myocardial infarction in 
rats subjected to cardiac I/R injury 24 hours post-exposure.  Our results maintain that IT 
exposure to nanoparticles exacerbates myocardial infarction in a male rat model.  We further 
tested the possibility that route of exposure may uniquely alter the I/R injury between IT and IV 
exposure to C60.  This did not appear to be the case in male rats as shown in Figure 7.  However 
the extent of post-I/R myocardial infarction in female rats was significantly larger in the IT C60 
exposed female group compared to the IV C60-exposed female group, suggesting that gender 
may influence the biological response to C60 exposure. 
 
Though post-I/R myocardial infarct sizes were not greatly different between IT and IV C60 
exposed males, serum IL-6 and MCP-1 concentrations were significantly elevated post-I/R in the 
IV C60 group compared to the IT C60 group.  It is unclear if these elevated serum components 
found after cardiac I/R contributed to the infarct expansion or were merely a reflection of the 
infarct size.  Further, it is unclear as to why male rats produced an IL-6/MCP-1 response 
following I/R in the IV C60 group but the female group did not.  We can speculate that perhaps a 
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link between cardioprotection and estrogen may also contribute to reduced IL-6 and MCP-1 
release in response to cardiac I/R.  In any case, IL-6 and MCP-1 have each been linked to 
impaired fibrinolysis/hemostasis following exposure to particulate matter (20; 48), which can 
promote thrombi-dependent zones of no reflow in the myocardium during I/R and exacerbate 
infarction.  IL-6 is associated with acute myocardial infarction (3) and promotes the release of C-
reactive protein, an acute-phase protein linked to myocardial infarction and increased production 
of MCP-1 (142).  MCP-1 is involved in neutrophil and macrophage recruitment into the 
myocardial risk area following I/R, and the release of MCP-1 following I/R injury has been 
implicated in diminished vagal nerve activity (26).  Given the MCP-1 concentrations reported 
herein and the report that ultrafine carbon particle exposure depresses vagal tone (68), the 
assessment of vagal tone following C60 exposure may be important in future studies. 
 
We also examined pharmacological responsiveness of isolated LAD in order to link C60 
exposure to enhanced coronary artery tone.  Vascular tone is an important physiological 
determinant of tissue perfusion and blood flow by impacting artery diameter and vascular 
resistance.  As vascular tone increases, vessel diameter decreases and thus perfusion flow 
decreases (5).  Coronary perfusion of the myocardial zone at risk for infarction during I/R can 
occur by collateral flow during ischemia and reflow during reperfusion.  Enhanced coronary 
arterial tone due to particle exposure could impair collateral flow during ischemia and promote 
zones of no reflow during reperfusion.  The LAD from IT C60 exposed male rats did show a 
trend for sensitized 5-HT mediated vascular smooth muscle contraction in our initial assessment 
of a vascular contribution to the cardiac I/R injury following IT exposure to C60.  Those LAD 
experiments also indicated that IV C60 exposure may have impacted vascular tone uniquely 
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from IT exposure to C60 by promoting impaired ACh endothelium-dependent vascular smooth 
muscle relaxation in the LAD.  Unexpectedly, these experiments indicated that in male rats, 
LAD from the IT vehicle group had diminished ACh responsiveness when compared to the naïve 
group.  In female rats, 5-HT responsiveness and ACh responses were only minimally altered, but 
a rightward shift in the LAD relaxation response to ACh in the IV C60 group was noticeable.  
The larger changes in the pharmacological assessments of female LAD came in the SNP 
concentration response studies, in which the route of exposure seemed to play a role.  In these 
experiments the female IT C60 group had diminished responsiveness to the NO donor SNP.  
This response was not recapitulated in the female IV C60 group and the response also offers a 
possible explanation for why the female IT C60 group had larger I/R infarct sizes than the IV 
C60 group. 
 
It is possible that slight shifts toward enhanced vascular tone during pharmacological 
assessments of LAD segments may function as an indicator of more robust vascular tone in the 
greater coronary circulation, especially during a period of cardiac reperfusion following an 
ischemic bout.  We have previously reported that one day after IT exposure to MWCNT in rats, 
isolated LAD segments generated slightly more stress in response to ET-1 but coronary flow was 
significantly depressed during post-ischemic reperfusion of isolated Langendorff rat hearts (159).  
Those enhanced isolated LAD ET-1 responses appeared to be associated with the COX pathway, 
a physiological response mechanism documented in various vascular beds following pulmonary 
exposure to nanoparticles (88; 95).  These reports prompted us to examine COX-dependent ET-1 
stress responses in isolated LAD from rats exposed to IT C60 and vehicle.  Maximal stress 
responses to ET-1 were more pronounced in the IT C60 exposed group compared to the IT 
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vehicle group.  Inhibition with 10 μM Indomethacin, a general COX inhibitor, prevented the 
increased LAD stress in response to ET-1 seen in the IT C60 group and had no effect in LAD 
from IT vehicle exposed rats.  These data support our hypothesis that enhanced coronary tone 
may have contributed to exacerbation of post-I/R myocardial infarction we found in the IT C60 
exposed rats as compared to the IT vehicle exposed rats.  As with the PAI-1 and ACh data we 
did note that ET-1 Hillslope values were diminished in the vehicle group compared to the naïve 
group. 
 
The findings in this study provide support that the cardiovascular system as a whole is 
susceptible to nanoparticle exposure, especially at the pulmonary interface.  While the entire set 
of mechanisms that contribute to exacerbation of I/R infarction are unclear, the vascular system 
appears to contribute to the deleterious cardiovascular consequences of nanoparticle exposure.  
The arterial system must maintain appropriate sensitivity to stimuli present in the immediate 
extracellular environment in order to adequately respond to the perfusion needs of the tissue and 
organ.  If the ability of the arterial system loses its ability to respond to stimuli appropriately, the 
homeostatic window for organ perfusion may narrow and may leave the tissue/organ susceptible 
to injury should an insult arise.  It appears from our data reported here, and in previous work 
(159), that 24 hours following nanoparticle exposure, pharmacological responsiveness to 
chemical ligands may be disrupted in coronary arteries.  Our findings of coronary dysfunction 
following nanoparticle exposure are also consistent with other investigations into coronary 
endpoints following nanoparticle exposure (95; 111; 153).  Such changes in coronary artery 
physiology can have serious detrimental health effects, especially during an ischemic emergency. 
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5.5. Chapter 5 conclusion 
Chapter 5 demonstrates that the heart is susceptible to I/R injury 24 hours following IT or IV 
exposure to C60 despite minimal pulmonary inflammation.  Novel to our initial predictions, 
administration of IV C60 also promoted infarct expansion following cardiac I/R 24 hrs post-
exposure, suggesting that translocation of C60 to the vascular compartment following pulmonary 
exposure is not solely responsible for infarct expansion during I/R.  We also offer evidence that 
the mechanisms that drive that injury may be unique from IT exposure.  These mechanisms 
include differential impacts on the coronary vasculature that promote enhanced coronary tone.  
These ranged from enhanced ET-1 stress generation to depressed ACh responsiveness.  
Additionally there may be some gender sensitivity to C60 administration routes.  IV exposure to 
C60 may uniquely modulate cytokine release during cardiac I/R.  We further caution that the 
choice of vehicles and dispersants used may have uniquely alter arterial responsiveness and have 
further unexpected cardiovascularconsequences.  Since C60 applications are growing in industry 
and medicine, awareness of potential cardiovascular consequences of exposure may improve 
safety regulations, broaden the medical uses of C60 through directed toxicity, and improve 
physicochemical modifications of C60.
CHAPTER 6 
INTEGRATED DISCUSSION AND CONCLUSION 
 
6.1. Integrated discussion 
6.1.1. Summary of findings 
Experiments from Specific Aim 1 demonstrated that pulmonary exposure to MWCNT 24 hours 
prior to cardiovascular assessment resulted in exposure mass-dependent increases in PVC at 
baseline (Figure 3.1).  The 100 g MWCNT group also displayed increased in TXB2 
concentration in coronary effluents at baseline but the difference was not statistically significant 
(Figure 3.1).  After 20 minutes of ischemia, hearts isolated from rats exposed to 100 µg of 
MWCNT demonstrated significant depressions in early coronary reperfusion flow (Figure 3.2), 
concomitant with significantly increased ET-1 concentration in coronary effluents and TXB2 
concentrations that were not significantly elevated (Figure 3.2).  Hearts isolated from rats 
exposed to MWCNT showed had shortened time into reperfusion before the first episode of 
VT/VF occurred but the differences were not statistically different (Figure 3.4).  Following the 
reperfusion period hearts from the 100 g MWCNT group had significantly larger infarct sizes 
than the infarctions that resulted in hearts from rats instilled with vehicle, and rats instilled with 1 
or 10 g of MWCNT had significant losses in LVDP by the end of reperfusion when compared 
to the vehicle group (Figure 3.4). 
 
Experiments from Specific Aim 2 demonstrated that 24 hours after pulmonary exposure to 100 
g of MWCNT, isolated LAD segments yielded enhanced stress generation in response to 
increasing concentrations of ET-1 by wire myography compared to LAD isolated from the 
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vehicle group (Figure 4.1).  The enhanced stress response to ET-1 in the MWCNT group was 
also evident using non-linear regression analysis.  However, examination of LAD responses to 
the TXA2 mimetic U46619 did not yield increases in coronary artery stress following MWCNT 
exposure but non-linear regression analysis of the vehicle and MWCNT group curves did 
indicate significant differences between the two groups (Figure 4.1).  Our investigation into the 
enhanced ET-1-mediated coronary artery stress response of the MWCNT group indicated the 
response was dependent on TXS, TP (Figure 4.5) and COX-2 signaling, with indication of a 
COX-1 element (Figure 4.4) according to non-linear regression analysis.  Evidence that the 
enhancement of ET-1-mediated coronary artery stress was due to endothelial/ETBR-dependent 
mechanisms was minimal and further investigations are necessary to clarify the role of these 
elements in augmentation of LAD stress generation following MWCNT exposure. 
 
Experiments from Specific Aim 3 demonstrated that the hearts were also susceptible to I/R injury 
expansion, 24 hours following IT exposure to C60 in male and female rats (Figure 5.1), with 
minimal pulmonary inflammation (Tables 5.2 and 5.3).  One day following IV exposure to C60 
in male and female rats, myocardial infarction was also worsened in response to I/R (Figure 5.1).  
Post-cardiac I/R serum cytokines IL-6 and MCP-1 were both elevated in the male IV C60 group 
when compared to the male IV vehicle, male IT C60, and female IV C60 groups (Figure 5.2).  
Experiments from Specific Aim 3 also yielded data suggesting that IT exposure to C60 in males 
results in enhanced ET-1-mediated coronary artery stress response not seen in following IV 
exposure to C60 in males or C60 exposure by both routes in females (Figure 5.5).  Further 
experiments demonstrated that the enhanced LAD stress response to ET-1 in IT C60 instilled 
males was sensitive to Indomethacin, a response that was not recapitulated in LAD isolated from 
127 
 
IT vehicle instilled males (Figure 5.6).  We did provide evidence unique to LAD isolated from 
IV C60 exposed male rats, which demonstrated desensitized ACh-mediated relaxation compared 
to LAD isolated from IV vehicle exposed males (Figure 5.3).  LAD isolated from IT C60-
instilled female rats demonstrated diminished coronary artery VSMC relaxation in response to 
SNP when compared to isolated LAD from IV vehicle-instilled females (Figure 5.4). 
 
6.1.2. Considerations 
6.1.2.1. Particle characteristics 
This dissertation focuses on 2 types of carbon-based ENP: MWCNT and C60.  These ENP have 
similar chemical composition but very different aspect ratios.  Because the carbon structures of 
MWCNT and C60 are hydrophobic, they required a dispersion media in order to increase their 
solubility and stability in aqueous solution.  In experiments designed to address Specific Aims 1 
and 2 we utilized an intratracheal instillation of MWCNT, the results for which can be found in 
Chapters 3 and 4.  We selected a medical grade pulmonary surfactant (Infasurf™) diluted to 10% 
in saline for the MWCNT suspensions.  The experiments described for Specific Aim 3 utilized 
intratracheal and intravenous delivery of C60, the results for which can be found in Chapter 5.  
The intravenous route of exposure in this study made the use of a pulmonary surfactant less 
desirable (169).   Instead, we selected PVP, a water-soluble polymer often used to increase the 
water solubility of C60 (77), diluted to 1.4% in saline.  The difference in dispersion media and 
suspension stabilities are important factors to consider in the interpretation of results across the 
MWCNT and C60 studies.  We analyzed suspension stability by assessing zeta potential.  The 
MWCNT had a zeta potential of -44.6 mV (Tables 3.1 and 6.1) in the suspensions used in 
experiments reported in Chapters 3 and 4, indicating that MWCNT were much more stable in 
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suspension than the C60 used in experiments reported in Chapter 5, which had a zeta potential of 
1.7 mV in suspension (Tables 5.1 and 6.1). 
 
Despite the use of dispersion media, MWCNT and C60 can still agglomerate in solution, thus 
physical characterization of the particles in solution is necessary in order to understand the 
working characteristics of suspensions that rats would be exposed to.  We analyzed the MWCNT 
and C60 suspensions by dynamic light scattering in order to obtain hydrodynamic sizes.  Our 
MWCNT suspensions used in experiments from Specific Aims 1 and 2, as reported in Chapters 3 
and 4, demonstrated bimodal size distributions with the major peak occurring at 200 nm and a 
smaller peak occurring 1000 nm (Tables 3.1 and 6.1).  Assessing MWCNT hydrodynamic size 
by dynamic light scattering can be problematic due to the aspect ratio of MWCNT.  For example, 
the bimodal distribution of peak values for MWCNT in suspension could have either indicated 
(i) the presence of two major size fractions of MWCNT agglomerates at 200 and 1000 nm; or (ii) 
MWCNT agglomerate diameter at 200 nm and MWCNT agglomerate length at 1000 nm.  
Conversely, assessment of C60 hydrodynamic size by dynamic light scattering during Specific 
Aim 3 as reported in Chapter 5, was less problematic, yielding one peak during each 
measurement with a mean of 371 nm (Tables 5.1 and 6.1).  The extent of MWCNT and C60 
agglomeration is also able to impact particle numbers in suspension.  We analyzed particle 
numbers of the MWCNT and C60 suspensions by flow cytometry.  In Chapter 3 we reported that 
100 g MWCNT instillation suspension contained 37,147 ± 625 particles per 10 L of 
suspension (Table 3.1).  In Chapter 5 we reported that C60 suspensions contained 25,791 ± 1351 
particles per 10 L of suspension (Table 3.1). 
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Table 6.1 Particle suspension comparisons 
 
Comparison of MWCNT and C60 suspensions physical characterization (mean ± SEM) 
MWCNT C60 
Zeta potential -44.6 mV 1.7 mV 
Hydrodynamic size, nm 200 ± 50, 1000 ± 150 371 ± 0.6 
Particle mass (per rat) 100 g 28 g 
Particle number (per rat) 742,940 ± 12,500 515,820 ± 27,020 
Calculated surface area (per rat) 467 mm
2
 224 mm
2
 
Surface area calculation for MWCNT based on tube surface area (2πrh; r was taken as 100 
and h was taken as 1000 nm) and C60 based on sphere surface area (4πr2; r was taken as 
186 nm) 
 
 
6.1.2.2. Particle dosimetry 
A recent publication by Erdely et al .identified a mean airborne mass concentration of 10.6 
µg/m
3
 MWCNT across 8 different facilities that handle carbon nanotubes in the United States, 
which was calculated to correspond with a human alveolar deposition of 4.07 µg/day (49).  This 
suggests that airborne concentrations of MWCNT are being relatively well controlled in the 
facilities investigated.  Scenarios and locations in which safety measures are not in place to 
minimize airborne particle dispersal are likely of low probability, but in a study designed to 
mimic such conditions while weighing and moving dry materials, MWCNTwere found to range 
from 4,514 – 123,403 particles/L of air (79).  Considering that average tidal volume in humans is 
500 mL of air and average respiration rate is 12 breaths a minute, humans breathe approximately 
360 L air/hour on average (11).  This could potentially result in a deposition of 1,625,040 – 
44,425,080 MWCNT particles into the lungs in 1 hour.  In experiments from Specific Aim 1, 
which are reported in Chapter 3 of this dissertation, we selected the use of 100 µg, 10 µg and 1 
µg of MWCNT to compare against vehicle exposure.  This allowed us to develop an exposure 
mass-response relationship for MWCNT and isolated cardiac I/R injury.  In experiments from 
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Specific Aim 2, which are reported in Chapter 4, we utilized 100 µg MWCNT to compare 
against vehicle exposure because coronary flow was significantly depressed during early 
reperfusion, concomitant with increased ET-1 concentration in coronary effluents during early 
reperfusion in the 100 g MWCNT group compared to vehicle during experiments from Specific 
Aim 1 (Figure 3.2).  Based on calculations from the flow cytometry data, the 100 g MWCNT 
group exposure mass corresponded with approximately 742,940 ± 12,500 particles per rat (Table 
6.1).  Considering the difference in a male rat at approximately 300 g and an ideal adult male 
human at 70 kg (4), humans are approximately 233.33 times larger than a rat.  If 742,940 
particles of MWCNT is multiplied by 233.33, the particle number would be >173 Million.  This 
would require between 3-107 hours of constant occupational exposure in work conditions with 
no safety measures to reduce the number of airborne MWCNT.  This means that the IT MWCNT 
instillation model used in this dissertation describes an unlikely real world scenario in terms of 
modern day occupational exposure. 
 
In experiments from Specific Aim 3, which are reported in Chapter 5, because of the solubility of 
C60, we could not achieve the same mass concentration of the 100 g MWCNT instillation 
suspension (0.5 g/L).  Instead we examined the highest achievable concentration (0.14 µg/µL) 
of PVP formulated C60, which translated to 28 µg of C60 exposure to compare against the 
vehicle group.  Based on calculations from flow cytometry data, the 28 g C60 exposure mass 
translated to approximately 515,820 ± 27,020 particles per rat (Table 6.1).  While it is not 
expected that airborne concentrations of C60 would be much higher than those found in modern 
facilities handling MWCNT with safety measures in place (49), a study designed to test airborne 
C60 concentrations in a occupational environment without safety measures reported to C60 
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particle numbers to range between 23,856 – 53,119 particles/L of airresearch laboratories (79).  
Based on the same considerations made for MWCNT, C60 deposition in human lungs could 
potentially range from 8,588,160 – 31,871,400 particles of C60 in 1 hour.  Based on the same 
human to rat size difference factor, if 515,820 particles of C60 is multiplied by 233.33, the 
particle number would be >120 Million, which would take between 4-14 hours of constant 
occupational exposurein work conditions with no safety measures to reduce the number of 
airborne C60.  This means that the IT C60 instillation model used in this dissertation describes 
an unlikely real world scenario in terms of modern day occupational exposure. 
 
In this dissertation we wanted to make broad comparisons across the MWCNT and C60 studies.  
Therefore it should be noted that despite the difference in exposure mass between the MWCNT 
and C60 studies, the differences in the sizes and aspect ratios of MWCNT and C60 in their 
respective suspensions allows us to consider the cardiovascular endpoints as they relate to 
differences in calculated particle surface area and particle number dosimetries (see Table 6.1). 
Rats in the MWCNT studies were exposed to nearly 4 times the particle mass than rats in the 
C60 study (100 µg vs. 28 µg).  However, when the exposure is considered by particle numbers, 
we delivered only 30% more MWCNT particles than C60 particles to each rat.  Furthermore, 
based on approximated calculations, rats exposed to MWCNT were only exposed to about half 
of the particle surface area than rats exposed to C60.  The only truly common endpoint examined 
between IT MWCNT and IT C60 studies was the cumulative concentration responses to ET-1 in 
isolated LAD.  As presented in Figure 6.1, when the increased LAD stress responses from both 
ENP groups (Figure 6.1A) are considered as a function of different dosimetries, the greatest 
difference between IT MWCNT and IT C60 responses occurred as a function of mass (Figure 
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6.1B).  The least difference between IT MWCNT and IT C60 response occurred as a function of 
particle number (Figure 6.1C).  When the difference between IT MWCNT and IT C60 responses 
were taken as a function of calculated surface area (Figure 6.1D), the difference was less than 
that of exposure mass and greater than that of particle number.  One possible explanation for the 
difference in LAD responses when taken as a function of calculated surface area is a potential 
difference in MWCNT and C60 biological surface area interaction.  Considering the differences 
in MWCNT and C60 agglomerate size and aspect ratios, it may be possible that the amount of 
particle surface area that interacts with biological tissue and thus initiating a response mechanism 
may be different between the two ENP.  This evidence suggests that C60 may potentially induce 
greater cardiovascular toxicity than MWCNT on a per mass basis, but that the responses to C60 
and MWCNT appear to be normalized as a function of particle number and/or particle surface 
area.  
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Figure 6.1 Coronary artery endothelin-1 stress responses as a function of dosimetry 
(A) ET-1 stress responses from male rats exposed either to IT MWCNT or IT C60 normalized to 
each respective vehicle group.  (B) ET-1 stress responses from male rats exposed either to IT 
MWCNT or IT C60 normalized to each respective vehicle group, and presented as a function of 
ENP mass.  (C) ET-1 stress responses from male rats exposed either to IT MWCNT or IT C60 
normalized to each respective vehicle group, and presented as a function of ENP particle 
number.  (D) ET-1 stress responses from male rats exposed either to IT MWCNT or IT C60 
normalized to each respective vehicle group, and presented as a function of calculated surface 
area. 
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6.1.3. Interpretation of results 
The literature review indicated that populations exposed to relatively high levels ofparticulate 
matter have increased risks for cardiovascular disease.  However, while the cardiovascular 
detriments associated with pulmonary exposure to NP are expected and evident, the 
physiological mechanisms by which the cardiovascular derangements are brought about are 
enigmatic.  We proposed that pulmonary exposure to ENP could promote intrinsic changes in the 
heart and coronary vasculature that could drive expansion of myocardial infarction after I/R.  In 
Chapter 3 we provided evidence that pulmonary exposure to MWCNT generated intrinsic 
changes in the heart that enhanced cardiac arrhythmogenesis when neurohumoral influences 
were removed.  With the exception of resident inflammatory cells, this left the possibility that 
local autonomic/paracrine signaling, altered coronary perfusion, and/or cellular dysfunction in 
nodal/conducting tissue may have been contributing factors.  The only evidence we were able to 
uncover at baseline that provided a possible explanation for the aberrant ECG and increased PVC 
generation in the MWCNT groups was the trend (P = 0.06) for increased TXB2 concentration in 
the coronary effluents from the 100 g MWCNT group at baseline.  In any case, this finding is 
consistent with cardiac arrhythmogenic responses documented following exposure to air 
pollution particulate matter (69; 80; 83).  More substantial evidence that IT MWCNT instillation 
had caused alterations in intrinsic factors of the heart was found during early reperfusion.  These 
manifested through increased ET-1 concentrations within the coronary effluents and depression 
of coronary flow.  Increased ET-1 release has also been documented following exposure to air 
pollution particulate matter and myocardial infarction (80).  By the end of reperfusion protocols 
reported in Chapter 3, LVDP was significantly reduced in hearts isolated from 1 and 10 g 
MWCNT-instilled rats and infarct size was significantly larger in hearts isolated from rats 
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instilled with 100 g MWCNT.  These findings support a generalized hypothesis that pulmonary 
exposure to ENP can cause cardiovascular detriments within the heart itself, which could 
possibly be broadened to include augmentation of local inflammatory cells responses residing 
within heart tissue.  Perhaps more importantly we learned that that there was an underlying 
correlation between the number of PVC that occurred at baseline and the size of myocardial 
infarction following I/R (Figure 6.2).   Therefore, examining individuals for sustained PVC who 
have recently been exposed to inhalation of high levels of MWCNT or other ENP in 
occupational settings, and potentially even other NP in the environment, may potentially indicate 
an increase in the susceptibility for cardiac I/R injury. 
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Figure 6.2 In Chapter 3 premature ventricular contractions from baseline correlated 
with myocardial infarct size following cardiac ischemia/reperfusion 
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In Chapter 4 we uncovered evidence indicating that isolated LAD from male rats instilled with 
MWCNT responded to ET-1 with enhanced stress.  This supported Chapter 3 findings that hearts 
isolated from MWCNT exposed rats had increased effluent ET-1 concentrations and depressed 
coronary flow during early reperfusion.  Subsequent studies in Chapter 4 indicated that COX-2 
and TP were involved in the enhanced ET-1-mediated coronary artery stress production in the 
MWCNT group.  Figure 6.3 shows a flow chart proposing how MWCNT exposure results in 
enhanced coronary stress in response to ET-1.  These findings, while unique in regards to 
enhanced ET-1 stress responses in LAD, are in agreement with another report that pulmonary 
exposure to MWCNT can adversely impact coronary arteries (153).  
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Figure 6.3 Proposed mechanism of increased coronary artery stress in response to ET-1  
  following pulmonary exposure to multi-walled carbon nanotubes(159) 
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Considering the rate that new ENP are being developed, establishing a physiological mechanism 
that can be used to classify ENP as potentially cardiotoxic would provide an important tool in 
toxicological assessments of new ENP that come to market.  To this end we examined C60 
exposure using the in situ cardiac I/R endpoint previously established in our laboratory and the 
isolated coronary artery assessment of ET-1-mediated stress production via wire myography 
established with in Chapter 4.  We also examined IT and IV exposure routes because (i) C60 has 
potential medical uses like contrast imaging agents and drug delivery devices that could require 
C60 be delivered IV and (ii) the size and shape of C60 should give it a relatively high probability 
to translocate through the lung and into the vascular compartment following pulmonary 
exposure.  Comparing IT and IV responses should provide a means to potentially assess if 
detrimental cardiovascular responses to IT C60 are due to an interaction at the pulmonary 
interface or possibly due to translocation into circulation.  The initial finding was that cardiac I/R 
infarction expanded in male rats exposed to either IT or IV C60.  This finding provides some 
plausibility to the claim that IT C60 translocation from the lung to the vascular compartment was 
responsible for cardiac I/R infarct expansion, but further research would be needed to 
substantiate that claim.  Alternatively, we uncovered stronger evidence to the contrary, in which 
serum cytokine profiles following cardiac I/R and isolated LAD experiments both suggested that 
the mechanisms responsible for cardiac I/R injury exacerbation are likely unique between IT and 
IV C60 exposure. 
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The common link between IT MWCNT and IT C60 exposed male rats was that the exposure 
resulted increased LAD stress in response to ET-1 when compared to their respective vehicle 
groups.  In both ENP groups, the LAD responses to ET-1 were returned to the stress level seen in 
vehicle control groups, with little change in ET-1 stress responses found in LAD from the 
vehicle groups inhibited with Indomethacin.  This suggests that COX is likely the contributing 
source of enhanced ET-1-mediated stress in LAD isolated from IT ENP instilled rats.  These 
findings, while exciting, must be interpreted with caution as ET-1 is a pleiotropic peptide and is 
influential in the cardiovascular system in many ways (see Figure 6.4) (58).  Altered ET-1 
responses in coronary arteries can be detrimental, as data from this dissertation suggests.  
However, if altered physiological responses to ET-1 following ENP exposure are not confined to 
coronary arteries, then ET-1 signaling may be of greater importance to examine following 
pulmonary exposure to ENP. 
 
It should also be noted that experiments for this project utilized IT exposures in rats.  Given that 
rats are obligatory nose breathers and that IT instillation bypasses nasal tissue, evidence that the 
LAD/ET-1/COX responses are likely dependent on ENP exposure at the pulmonary interface.  
Also, while this dissertation addressed an acute exposure associated with relatively large mass 
exposures to ENP, real world exposures in humans may be of lower mass, but small changes in 
physiological responses to ligands like ET-1 as described in Figure 6.4 could provide an 
explanation for the high incidence of cardiovascular disease and mortality that have been linked 
to airborne particulate matter.  Therefore based on the evidence provided in this dissertation, ET-
1/COX-associated mechanisms should be carefully examined following ENP inhalation 
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exposures in order to determine if long term exposure to ENP could potentially increase the 
incidence of cardiovascular disease and mortality in individuals chronically exposed to ENP. 
 
 
Figure 6.4 Potential cardiovascular consequences of dysregulated endothelin-1   
  signaling(58) 
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6.2. Dissertation conclusion 
This dissertation has outlined important points from the literature that merit concern that the 
cardiovascular system could be particularly susceptible to ENP-induced toxicity.  Experiments 
were performed herein that indicated the potential for pulmonary exposureto ENP to produce 
dysfunction in heart rhythm and the coronary artery ET-1/COX axis.  We provide evidence that 
ENP have the potential to generate cardiovascular detriments unique to exposure route, and 
further that males and females may respond to ENP exposure through different mechanisms.  By 
considering particle dosimetry, it appears that isolated coronary artery responses to ET-1 
following MWCNT or C60 exposure can be normalized when they are considered as a function 
of particle number/particle surface area.  In either case, pulmonary exposure to MWCNT or C60 
produced augmented coronary artery responses to ET-1.  Given the broad reaching consequences 
of altered ET-1signaling throughout the cardiovascular system, if exposure to ENP is a concern, 
therapeutic targeting of the ET-1 and/or COX signaling pathways could potentially alleviate 
cardiovascular detriments associated with ENP exposures.
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